

PERSONAL INFORMATION **Emilio Perucca**WORK EXPERIENCE

March 2001- Present **Professor of Clinical Pharmacology**
University of Pavia Medical School (Italy)

March 2009- Present **Director, Clinical Trial Centre**
National Institute of Neurology, IRCCS Mondino Foundation (Italy)

December 2018- Present **Professor, Chair of Clinical Pharmacology in Pediatric Epilepsy**
Monash University, Melbourne (Australia)

EDUCATION AND TRAINING

1978- 1982 **Specialization in Neurology (Board Certification)**
University of Pavia (Italy)

1977- 1980 **Ph.D in Clinical Pharmacology**
University of London (United Kingdom)

1975- 1978 **Specialization in Endocrinology (Board Certification)**
University of Pavia (Italy)

1969- 1975 **M.D. Degree, with honours**
University of Pavia (Italy)

ADDITIONAL INFORMATION

Expertise Clinical Pharmacology of Antiepileptic Drugs. Treatment of Epilepsy. Clinical Trial Design. Outcome Assessment.

Publications H-INDEX CITATION INDEX (2019)
H-Index (Scopus): 80
Citation index: 24,939

LIST OF PUBLICATIONS (Articles in scientific journals)

1. PERUCCA, E., TEGGIA, M. and TONINI, M. Site of action of catecholamines on the peristaltic reflex. Boll. Soc. It. Biol. Sper. (Napoli) 52, 581-586, 1976
2. PERUCCA, E, TEGGIA, M. and TONINI, M. Peristaltic reflex: supersensitivity to catecholamines.

- I) The muscular site of action. *Boll. Soc. It. Biol. Sper. (Napoli)* 52, 568-574, 1976
3. PERUCCA, E., TEGGIA, M. and TONINI, M. Peristaltic reflex: supersensitivity to catecholamines.
- II) The inhibition of the nervous structures. *Boll. Soc. It. Biol. Sper. (Napoli)* 52, 575-580, 1976
4. LECCHINI, S., D'ANGELO, L., TONINI, M., PERUCCA, E., GATTI, G. and TEGGIA D.M. Effects of some autonomic drugs on the electrical activity of intestinal circular muscle. *Boll. Soc. It. Biol. Sper. (Napoli)* 52, 1158-1161, 1976
5. TEGGIA, D.M., PERUCCA, E., and TONINI, M. Effects of pentazocine on gastrointestinal smooth muscle. I) Colon. *Boll. Soc. It. Biol. Sper. (Napoli)* 52, 587-590, 1976
6. TEGGIA, D.M., PERUCCA, E., and TONINI, M. Effects of pentazocine on gastrointestinal smooth muscle. II) Ileum and Oddi's sphincter. *Boll. Soc. It. Biol. Sper. (Napoli)* 52, 591-594, 1976
7. DORMIA CRISTALLO, L., DE PASCALE, V., CREMA, A., CRAVERI, F., PERUCCA, E. and TEGGIA DROGHI, M. Attivita' antibatterica dell'associazione trimethoprim-sulfametossipirazina. *L'Igiene Moderna (Roma)* 69, 261-284, 1976
8. FRIGO, G.M., PERUCCA, E., TEGGIA-DROGHI, M., GATTI, G. VISINTINI, D., CALZETTI, S. and POLONI, M. Rilievi epidemiologici sui livelli plasmatici di difenilidantoina in 130 pazienti epilettici in trattamento cronico. *Riv. Patol. Nerv. Ment. (Firenze)* 97, 305-314, 1976
9. PERUCCA, E. and RICHENS, A. Interaction between phenytoin and imipramine. *Brit. J. Clin. Pharmacol. (London)* 4, 485-486, 1977
10. AHMAD, S., PERUCCA, E. and RICHENS, A. The effect of frusemide, mexiletine, (+)-propranolol and three benzodiazepine drugs on interictal spike discharges in the electroencephalograms of epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 4, 683-688, 1977
11. DE PASCALE, V., BAMONTE, F., CRAVERI, F., CREMA, A., PERUCCA, E. and TEGGIA DROGHI, M. Studio tossicologico dell'associazione trimethoprim-sulfametossipirazina. *L'Igiene Moderna (Roma)* 69, 261-284, 1977
12. GATTI, G., PERUCCA, E., CARAVAGGI, M., POLONI, M., FRIGO, G.M. and CREMA, A. Pharmacokinetics of phenytoin following intravenous administration in epileptic patients. *Il Farmaco (Ed. Pr.)(Pavia)* 32, 470-474, 1977
13. FRIGO, G.M., PERUCCA, E., TEGGIA, D.M., GATTI, G. MUSSINI, A. and SALERNO, J. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations. *Brit. J. Clin. Pharmacol. (London)* 4, 449-454, 1977
14. PERUCCA, E., GARRATT, A., HEBDIGE, S. and RICHENS, A. Water intoxication in epileptic patients receiving carbamazepine. *J. Neurol. Neurosurg. Psych. (London)* 41, 713-718, 1978
15. PERUCCA, E., GATTI, G. FRIGO, G.M. and CREMA, A. Pharmacokinetics of valproic acid after oral and intravenous administration. *Brit. J. Clin. Pharmacol. (London)* 5, 313-318, 1978
16. PERUCCA, E., GATTI, G. FRIGO, G.M., CREMA, A., CALZETTI, S. and VISINTINI, D. Disposition of sodium valproate in epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 5, 495-499, 1978
17. PERUCCA, E. Clinical consequences of microsomal enzyme induction by antiepileptic drugs. *Pharmacol. Ther. (Oxford)* 2, 285-314, 1978

18. PERUCCA, E., MAKKI, K. and RICHENS, A. Is phenytoin metabolism dose-dependent by enzyme saturation or by feed-back inhibition? *Clin. Pharmacol. Ther. (St. Louis)* 26, 46-51, 1978
19. FRIGO, G.M., LECCHINI, S., GATTI, G. PERUCCA, E. and CREMA, A. Modification of phenytoin clearance by valproic acid in normal subjects. *Brit. J. Clin. Pharmacol. (London)* 8, 553-556, 1979
20. PERUCCA, E. and RICHENS, A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. *Brit. J. Clin. Pharmacol. (London)* 8, 201-206, 1979
21. PERUCCA, E. and RICHENS, A. Reduction of oral availability of lignocaine by induction of first-pass metabolism in epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 8, 21-21, 1979
22. RUPRAH, M. PERUCCA, E. and RICHENS, A. Decreased serum protein binding of phenytoin in late pregnancy. *The Lancet (London)* ii, 316-317, 1980
23. PERUCCA, E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. *Ther. Drug Monit. (New York)* 2, 331-344, 1980
24. PERUCCA, E. Drug interactions in epilepsy. *Arquivos de Neuropsiquiatria (Sao Paulo)* 38, 331-340, 1980
25. BACK, D.J., BATES, M., BOWDEN, A., BRECKENRIDGE, A.M., HALL, M.J., JONES, H., MACIVER, M., ORME, M., PERUCCA, E., RICHENS, A., ROWE, P.H. and SMITH, E. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. *Contraception (Los Altos)* 22, 945-502, 1980
26. PERUCCA, E., BITTENCOURT, P. and RICHENS, A. Effect of dose increments on serum carbamazepine concentration in epileptic patients. *Clinical Pharmacokinetics (Auckland)* 6, 576-582, 1980
27. PERUCCA, E., HEDGES, A.M., MAKKI, K.A. and RICHENS, A. A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme inducing drugs. *Brit. J. Clin. Pharmacol. (London)* 10, 491-497, 1980
28. GRIFFITHS, A., HEBDIGE, S., PERUCCA, E. and RICHENS, A. Quality control in drug measurement. *Ther. Drug Monit. (New York)* 2, 51-59, 1980
29. PERUCCA, E., HEBDIGE, S., FRIGO, G.M., GATTI, G. LECCHINI, S. and CREMA, A. Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. *Clin. Pharmacol. Ther. (St. Louis)* 28, 779-789, 1980
30. PERUCCA, E. and RICHENS, A. Reversal by phenytoin of carbamazepine-induced water intoxication: A pharmacokinetic interaction. *J. Neurol. Neurosurg. Psych. (London)* 43, 540-545, 1980
31. PERUCCA, E., RUPRAH, M. and RICHENS, A. Altered drug binding to serum proteins in pregnant women: Therapeutic relevance. *Journal of the Royal Society of Medicine (London)* 74, 422-426, 1981
32. CALZETTI, S., FINDLEY, L.J. GREASY, M.A., PERUCCA, E. and RICHENS, A. Metoprolol and propranolol in essential tremor: A double-blind, controlled study. *J. Neurol. Neurosurg. Psych.*

(London) 44, 814-819, 1981

33. PERUCCA, E., PICKLES, H. and RICHENS, A. Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. *Clin. Pharmacol. Ther. (St. Louis)* 29, 425-433, 1981

34. PERUCCA, E. and RICHENS, A. Drug interactions with phenytoin. *Clinical Pharmacokinetics (Auckland)* 21, 120-137, 1981

35. PICKLES, H., PERUCCA, E., FISH, A. and RICHENS, A. Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor. *Clin. Pharmacol. Ther. (St. Louis)* 30, 303-310, 1981

36. PERUCCA, E., RUPRAH, M., RICHENS, A., PARK, B.K., BETTERIDGE, D.J. and HEDGES, A.M. Effect of low-dose phenobarbitone on five indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. *Brit. J. Clin. Pharmacol. (London)* 12, 592-596, 1981

37. PERUCCA, E. and RICHENS, A. The Ultrafree Drug Filters: Need for closer evaluation. *Ther. Drug Monit. (New York)* 3, 309-312, 1981

38. RUPRAH, M. PERUCCA, E. and RICHENS, A. Spuriously high values of unbound drug fraction in serum as determined by the new Ultrafree Anticonvulsant Drug Filters. *Brit. J. Clin. Pharmacol. (London)* 12, 753-756, 1981

39. CALZETTI, S., FINDLEY, L.J., PERUCCA, E. and RICHENS, A. Metoprolol in essential tremor. *The Lancet (London)* ii, 1227, 1981

40. CROLLA, T., ALBRICI, A., PARINI, J., GATTI, G. and PERUCCA, E. Escrezione urinaria di oxiracetam (ISF 2522) nel volontario sano. *Arch. Int. Med. (Parma)* 34, 407-413, 1982

41. CHEN S.S., PERUCCA, E., LEE J.N. and RICHENS, A. Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. *Brit. J. Clin. Pharmacol. (London)* 13, 547-552, 1982

42. COTTRELL, P.R., STREETE, J.M., BERRY, D.J., SCHAEFER, H., PISANI, F., PERUCCA, E. and RICHENS, A. Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs. *Epilepsia (New York)* 23, 307-313, 1982

43. PERUCCA, E. Pharmacokinetic interactions with antiepileptic drugs. *Clinical Pharmacokinetics (Auckland)* 7, 57-84, 1982

44. RIVA, R., ALBANI, F., BARUZZI, A., GALVANI, I. and PERUCCA, E. Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas-liquid chromatography: Methodological aspects and observations in epileptic patients. *Ther. Drug Monit. (New York)* 4, 341-352, 1982

45. PERUCCA, E. and CREMA, A. Interazioni farmacologiche nel trattamento dell'epilessia. *Basi Raz. Ter. (Padova)* 12, 797-808, 1982

46. CACCIABUE, L., PERUCCA, E. and CREMA, A. Farmaci antiepilettici in gravidanza, *Basi Raz. Ter. (Padova)* 12, 163-175, 1982

47. ALBANI, F., RIVA, R., PERUCCA, E. and BARUZZI, A. Interference of valproic acid in the

colorimetric determination of free fatty acids in plasma. *Clinical Chemistry (New York)* 28, 1398, 1982

48. GATTI, G., PERUCCA, E., LECCHINI, S., FRIGO, G.M., and CREMA, A. Pharmacokinetic interactions with antiepileptic drugs. *Int. J. Clin. Pharm. Res. (Geneva)* 11 (suppl.1), 95-100, 1982
49. TONINI, M., ONORI, L., LECCHINI, S. FRIGO, G.M., PERUCCA, E. and CREMA, A. Mode of action of ATP on propulsive activity in rabbit colon. *Eur. J. Pharmacol. (Amsterdam)* 82, 21-28, 1982
50. PERUCCA, E. and CREMA, A. Plasma protein binding of drugs in pregnancy. *Clinical Pharmacokinetics (Auckland)* 7, 336-352, 1982
51. CALZETTI, S., FINDLEY, L.J., PERUCCA, E. and RICHENS, A. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. *J. Neurol. Neurosurg. Psych. (London)* 45, 893-897, 1982
52. CALZETTI, S., FINDLEY, L.J., GREESTY, M.A., PERUCCA, E. and RICHENS, A. Effect of a single oral dose of propranolol in essential tremor: A double-blind controlled study. *Ann. Neurol. (Boston)* 13, 165-171, 1983
53. CALZETTI, S., FINDLEY, L.J., PERUCCA, E. and RICHENS, A. The response of essential tremor to propranolol: Evaluation of clinical variables governing its efficacy on prolonged administration. *J. Neurol. Neurosurg. Psych. (London)* 46, 393-398, 1983
54. ALBANI, F., RIVA, R., PROCACCIANTI G, BARUZZI, A. and PERUCCA, E. Free fraction of valproic acid: in vitro time-dependent increase and correlation with free fatty acid concentration in human plasma and serum. *Epilepsia (New York)* 24, 65-73, 1983
55. PERUCCA, E. and CREMA, A. Terapia farmacologica dell'epilessia e monitoraggio dei livelli plasmatici dei farmaci antiepilettici. *Medicina (Riv. Encicl. Med. It.)(Roma)* 3, 219-228, 1983
56. PERUCCA, E. Schede farmacologico-cliniche (Clonazepam, diazepam e nitrazepam - Carbamazepina - Etosuccimide e metosuccimide - Fenitoina - Fenobarbitale - Primidone - Trimetadione - Valproato di sodio). *Medicina (Riv. Encicl. Med. It.)(Roma)* 3, n. 3, 1983
57. FAGGI, L., CITTERIO, A., FRIGO, G.M., PERUCCA, E., LECCHINI, S. and GIANNETTI, A. Penicillin CSF levels following intravenous therapy in syphilitic patients. *Ital. J. Neurol. Sci. (Milano)* 4, 423-426, 1983
58. TONINI, M., ONORI, L., LECCHINI, S., FRIGO, G.M., PERUCCA, E., SALTARELLI, P. and CREMA, A. 5-HT mediated GABA excitatory responses in the guinea-pig proximal ileum. *Naunyn-Schmiedeberg's Arch. Pharmacol. (Heidelberg)* 324, 180-184, 1983
59. FRIGO, G.M., LECCHINI, S. CARAVAGGI, M., GATTI, G., TONINI, M., D'ANGELO, L., PERUCCA, E. and CREMA, A. Reduction in phenytoin clearance by cimetidine. *Eur. J. Clin. Pharmacol. (Heidelberg)* 25, 135-137, 1983
60. RIVA, R., ALBANI, F., CORTELLI, P., GOBBI, G., PERUCCA, E. and BARUZZI, A. Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady-state in epileptic patients. *Ther. Drug Monit. (New York)* 5, 191-196, 1983
61. RIVA, R., ALBANI, F., FRANZONI, E., PERUCCA, E., SANTUCCI, M. and BARUZZI, A. Valproic acid free fraction in epileptic children under chronic monotherapy. *Ther. Drug Monit. (New York)* 5, 197-200, 1983

62. TONINI, M., PERUCCA, E., MANZO, L., MARCOLI, M., D'ANGELO, L., SALTARELLI, P and ONORI, L. Dilazep: An inhibitor of adenosine uptake with intrinsic calcium antagonistic properties. *J. Pharm. Pharmacol. (London)* 35, 434-439, 1983
63. CROLLA, T., ALBRICI, A., GATTI, G., PARINI, J., PERUCCA, E., VISCONTI, M. and CREMA, A. Recovery urinario e biodisponibilita' di oxiracetam (ISF 2522) dopo somministrazione orale ed endovenosa in soggetti sani. *Arch. Int. Med. (Parma)* 35, 67-73, 1983
64. PERUCCA, E. Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies. *Clinical Pharmacokinetics (Auckland)* 9 (Suppl. 1), 71-78, 1984
65. RIVA, R., ALBANI, F., CONTIN, M., BARUZZI, A., ALTOMARE, M., MERLINI, G.P. and PERUCCA, E. Mechanism of altered drug binding to serum proteins in pregnant women: Studies with valproic acid. *Ther. Drug Monit. (New York)* 6, 25-30, 1984
66. ALBANI, F., RIVA, R., CONTIN, M., BARUZZI, A., ALTOMARE, M., MERLINI, G.P. and PERUCCA, E. Differential transplacental binding of valproic acid: Influence of free fatty acids. *Brit. J. Clin. Pharmacol. (London)* 17, 759-762, 1984
67. ALBANI, F., RIVA, R., BALDRATI, A., CORTELLI, P., PERUCCA, E., PROCACCIANTI, G. and BARUZZI, A. Plasma concentrations of propranolol and 4-hydroxy-propranolol at steady-state in neurological patients: Intersubject and intrasubject correlations with dose. *Int. J. Clin. Pharm. Res. (Geneva)* 4, 19-23, 1984
68. PERUCCA, E., GRIMALDI, R., GATTI, G., CARAVAGGI, M., CREMA, F., LECCHINI, S. and FRIGO, G.M. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: A comparison with other commercially available formulations. *Brit. J. Clin. Pharmacol. (London)* 18, 37-43, 1984
69. PERUCCA, E., GRIMALDI, R., GATTI, G., PIRRACCHIO, S., CREMA, F., and FRIGO, G.M. Pharmacokinetics of valproic acid in the elderly. *Brit. J. Clin. Pharmacol. (London)* 17, 665-669, 1984
70. TSANACLIS, L.M., ALLEN, J., PERUCCA, E., ROUTLEDGE, P.A. and RICHENS, A. Effect of valproate on free plasma phenytoin concentrations. *Brit. J. Clin. Pharmacol. (London)* 18, 17-20, 1984
71. GATTI, G., PERUCCA, E., FRIGO, G.M., NOTARANGELO, L.D., BARBERIS, L. and MARTINI, A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. *Brit. J. Clin. Pharmacol. (London)* 17, 423-431, 1984
72. RIVA, R., ALBANI, F., AMBROSETTO, G., CONTIN, M., CORTELLI, P., PERUCCA, E. and BARUZZI, A. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. *Epilepsia (New York)* 25, 476-481, 1984
73. PERUCCA, E., HEDGES, A., MAKKI, K.A., RUPRAH, M., WILSON, J.F. and RICHENS, A. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 18, 401-410, 1984
74. PERUCCA, E. and RICHENS, A. Alterations of drug toxicity in neuropsychiatric disease states. *Arch. Toxicol (Heidelberg) Suppl.* 7, 48-57, 1984

75. PERUCCA, E., ALBRICI, A., GATTI, G., SPALLUTO, R., VISCONTI, M. and CREMA, A. Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers. *Eur. J. Drug Metab. Pharmacok (Geneva)* 3, 267-274, 1984
76. PISANI, F., PERUCCA, E., PRIMERANO, G., AMENDOLA D'AGOSTINO, A., PETRELLI, A.M., FAZIO, A., OTERI, G., and DI PERRI, R. Single dose kinetics of primidone in acute viral hepatitis. *Eur. J. Clin. Pharmacol. (Heidelberg)* 27, 465-469, 1984
77. RIVA, R., CONTIN, M., ALBANI, F., PERUCCA, E., AMBROSETTO, G., GOBBI, G., CORTELLI, P., PROCACCIANTI, G. and BARUZZI, A. Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: Diurnal fluctuations and relationship with side effects. *Ther. Drug Monit. (New York)* 6, 408-413, 1984
78. BONATI, M., CASTELLI, D., TOGNONI, G., LEONE, N. and PERUCCA, E. Controllo di qualità nella determinazione dei livelli ematici dei farmaci antiepilettici: risultati di una indagine condotta presso 41 laboratori ospedalieri italiani. *Boll. Lega It. Epil. (Milano)* 47, 5-7, 1984
79. GRIMALDI, R., LECCHINI, S., CREMA, F. and PERUCCA, E. In vivo plasma protein interaction between valproic acid and naproxen. *Eur. J. Drug Metab. Pharmacok (Geneva)* 9, 359-363, 1984
80. CONTIN, M., RIVA, R., ALBANI, F., PERUCCA, E. and BARUZZI, A. Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: Interference with the 10,11-epoxide metabolite. *Ther. Drug Monit. (New York)* 7, 45-60, 1985
81. RIVA, R., ALBANI, F., CONTIN, M., PERUCCA, E., AMBROSETTO, G., GOBBI, G., SANTUCCI, M., PROCACCIANTI, G. and BARUZZI, A. Time-dependent interaction between phenytoin and valproic acid: Diurnal changes in free phenytoin concentration and fraction. *Neurology (Minneapolis)* 35, 510-515, 1985
82. TARTARA, A., FORMIGLI, L., CREMA, F., MAURELLI, M., PERUCCA, E., MARCHIONI, E., MANZO, L. and SAVOLDI, F. Alcohol interactions with typical and atypical antidepressants. *Neurobehavioural Toxicology and Teratology (Fayette Ville)* 7, 139-141, 1985
83. RIVA, R., CONTIN, M., ALBANI, F., PERUCCA, E., AMBROSETTO, G., PROCACCIANTI, G., SANTUCCI, M., and BARUZZI, A. Lateral gaze nystagmus in carbamazepine-treated epileptic patients: Correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. *Ther. Drug Monit. (New York)* 7, 277-282, 1985
84. RIVA, R., CONTIN, M., ALBANI, F., PERUCCA, E., LAMONTANARA, G. and BARUZZI, A. Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood. *Epilepsia (New York)* 26, 320-322, 1985
85. PERUCCA, E. and JACKSON, P. A controlled study of the suppression of tinnitus by lidocaine infusion: Relationship of therapeutic effect with serum lidocaine levels. *J. Laryngol. Otol. (London)* 99, 657-661, 1985
86. PERUCCA, E., GRIMALDI, R. and CREMA, A. Interpretation of drug levels in acute and chronic disease states. *Clinical Pharmacokinetics (Auckland)* 10, 498-513, 1985
87. CONTIN, M., RIVA, R., ALBANI, F., PERUCCA, E., LAMONTANARA, G. and BARUZZI, A. Alpha1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in children with epilepsy. *Eur. J. Clin. Pharmacol. (Heidelberg)* 29, 211-214, 1985

88. RIVA, R., CONTIN, M., ALBANI, F., PERUCCA, E., PROCACCIANTI, G. and BARUZZI, A. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. *Clinical Pharmacokinetics (Auckland)* 10, 524-531, 1985
89. BONATI, M., CASTELLI, D., LEONE, N., PERUCCA, E. and TOGNONI, G. Quality control in antiepileptic drug monitoring in Italy. *Drug Intell. Clin. Pharm. (Cincinnati)* 19, 913-915, 1985
90. BARZAGHI, N., and PERUCCA, E. Monitoraggio terapeutico della ciclosporina A: necessario, utile o... impraticabile? *Giorn. It. Chim. Clin. (Padova)* 10, 175-178, 1985
91. GRIMALDI, R., PERUCCA, E. and CREMA, A. Meccanismo d'azione dei farmaci antiipertensivi: Basi farmacologiche dell'impiego clinico. *Riv. Giov. Med. (Milano)* e, 37-44, 1985
92. TONINI, M., ONORI, L., PERUCCA, E., MANZO, L., DE PONTI, F. and CREMA, A. Depression by morphine of the excitability of intrinsic inhibitory neurons in the guinea pig colon. *Eur. J. Pharmacol. (Amsterdam)* 115, 317-320, 1985
93. TONINI, M., PERUCCA, E., MANZO, L. and CREMA, A. Lead inhibits cholinergic transmission in the guinea-pig myenteric plexus-longitudinal muscle preparation. *IRCS Med. Sci. (Lancaster)* 13, 940-941, 1985
94. PISANI, F., FAZIO, A., OTERI, G., RUELO, C., GITTO, C., RUSSO, F. and PERUCCA, E. Sodium valproate and valpromide: Differential interactions with carbamazepine in epileptic patients. *Epilepsia (New York)* 27, 548-552, 1986
95. PERUCCA, E., GRIMALDI, R., RUBERTO, G., GELMI, C., TRIMARCHI, F. and CREMA, A. Comparative kinetics of phenobarbital after administration of the acid and the propylhexedrine salt (barbexaclone). *Eur. J. Clin. Pharmacol. (Heidelberg)* 29, 729-730, 1986
96. GRIMALDI, R., PERUCCA, E., RUBERTO, G., GELMI, C., TRIMARCHI, F., HOLLMANN, M. and CREMA, A. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. *Eur. J. Clin. Pharmacol. (Heidelberg)* 29, 735-737, 1986
97. BARZAGHI, N., PERUCCA, E. and CREMA, A. Alterazioni dei parametri di laboratorio in corso di terapia con farmaci antiepilettici. *Giorn. It. Chim. Clin. (Padova)* 11, 1-27, 1986
98. D'ANGELO, L., GRIMALDI, R., CARAVAGGI, M., MARCOLI, M., PERUCCA, E., LECCHINI, S., FRIGO, G.M. and CREMA, A. A double-blind, placebo-controlled clinical study on the effect of a standardized ginseng extract on psychomotor performance in healthy volunteers, J. *Ethnopharmacol. (Dublin)* 16, 15-22, 1986
99. TONINI, M., ONORI, L., RIZZI, C.A., DE PONTI, F., PERUCCA, E., BUDASSI, P. and CREMA, A. Inhibitory action of capsaicin on cholinergic responses induced by GABAA agonists in the guinea-pig ileum. *Eur. J. Pharmacol. (Amsterdam)* 128, 273-276, 1986
100. PISANI, F., FAZIO, A., OTERI, G., PERUCCA, E., RUSSO, M., TRIO, R., PISANI, B. and DI PERRI, R. Carbamazepine-viloxazine interaction in patients with epilepsy. *J. Neurol. Neurosurg. Psych. (London)* 49, 1142-1145, 1986
101. PISANI, F., FAZIO, A., SPINA, E., ARTESI, C., PISANI, B., RUSSO, M., TRIO, R. and PERUCCA, E. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in

- epileptic patients receiving chronic anticonvulsant treatment. *Psychopharmacology* (Berlin) 90, 295-298, 1986
102. BARUZZI, A., CONTIN, M., PERUCCA, E., ALBANI, F. and RIVA, R. Altered serum protein binding of carbamazepine in disease states associated with an increased alpha1-acid glycoprotein concentration. *Eur. J. Clin. Pharmacol.* (Heidelberg) 31, 85-89, 1986
103. LEONE, N., BARZAGHI, N., MONTELEONE, M., PERUCCA, E., CERUTTI, R and CREMA, A. Farmacocinetica di cotrimazina dopo somministrazione singola e ripetuta. *Giorn. It. Chemioter.* (Torino) 33 (suppl. 5), 25-29, 1986
104. PISANI, F., FAZIO, A., PERUCCA, E., OTERI, G., ARTESI, C. and DI PERRI, R. Interazioni tra farmaci antiepilettici. Studio retrospettivo sui livelli sierici di una vasta popolazione di pazienti. *Acta Neurol.* (Napoli) 8, 329-333, 1986
105. COSI, V., CALLIECO, R., GALIMBERTI, C.A., MANNI, R., TARTARA, A., LANZI, G., BALOTTIN, U. and PERUCCA, E.. Studio controllato in doppio cieco dei potenziali evocati (VEP, BAEP, SEP) in corso di trattamento con vigabatrin. *Boll. Soc. It. Epil.* (Milano) 54/55, 249-250, 1986
106. TARTARA, A., MANNI, R., GALIMBERTI, C.A., HARDENBERG, J. and PERUCCA, E. Studio clinico controllato di vigabatrin nel trattamento dell'epilessia grave. *Boll. Soc. It. Epil.* (Milano) 54/55, 247-248, 1986
107. PERUCCA, E. Phenytoin: The problem of saturation kinetics. *Int. Epilepsy News* (Haarlem) 86, 3-4, 1986
108. TARTARA, A., MANNI, R., GALIMBERTI, C.A., HARDENBERG, J., ORWIN, J. and PERUCCA, E. Vigabatrin in the treatment of epilepsy: A double-blind, placebo-controlled study. *Epilepsia* (New York) 27, 717-723, 1986
109. LEONE, N., BARZAGHI, N., MONTELEONE, M., PERUCCA, E., CERUTTI, R and CREMA, A. Pharmacokinetics of cotrimazine after single and multiple doses. *Arzneim. Forsch.* (Aulendorf) 37, 70-74, 1987
110. TONINI, M., RIZZI, C.A., PERUCCA, E., DE PONTI, F., D'ANGELO, L., DEL VECCHIO, A. and CREMA, A. Depressant action of oxybutinin on the contractility of intestinal and urinary tract smooth muscle. *J. Pharm. Pharmacol.* (London) 39, 103-107, 1987
111. HOLLMANN, M., MULLER-PELTZER, H., GREGER, G., BRODE, E., PERUCCA, E., GRIMALDI, R. and CREMA, A. Pharmacokinetic - dynamic study on different oral biperiden formulations in volunteers. *Pharmacopsychiatry* (Stuttgart) 20, 72-77, 1987
112. PERUCCA, E. Quando e come utilizzare in clinica il dosaggio plasmatico dei farmaci. *Basi Raz. Ter.* (Padova) 17, 197-206, 1987
113. TONINI, M., ONORI, L., RIZZI, C.A., PERUCCA, E., MANZO, L. and CREMA, A. Involvement of substance P in the excitatory action of GABAA-agonists on cholinergic neurons in the guinea-pig ileum. *Naunyn-Schmiedeberg's Arch. Pharmacol.* (Heidelberg) 335, 629-635, 1987
114. PERUCCA, E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. *Pharmacol. Ther.* (Oxford) 33: 139-144, 1987
115. PERUCCA, E. Drug metabolism in pregnancy, infancy and childhood. *Pharmacol. Ther.* (Oxford) 34: 129-143, 1987

116. PISANI, F., FAZIO, A., ARTESI, C., OTERI, G., PISANI, B., ROMANO, F., PERUCCA, E. and DI PERRI, R. An epidemiological study of the clinical impact of pharmacokinetic drug interactions based on serum drug level analysis. *Ital. J. Neurol. Sci. (Milano)* 8, 135-142, 1987
117. PERUCCA, E., PARINI, J., ALBRICI, A., VISCONTI, M. and FERRERO, E. Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly. *Eur. J. Drug Metab. Pharmacok (Geneva)* 12, 145-148, 1987
118. GATTI, G., CREMA, F., ATTARDO-PARRINELLO, G., FRATINO, P., AGUZZI, F. and PERUCCA, E. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. *Ther. Drug Monit. (New York)* 9: 389-391, 1987
119. CREMA, F., PARINI, J., VISCONTI, M., PERUCCA, E. Effetto degli antacidi sulla biodisponibilita' del carbenoxolone. *Il Farmaco (Pavia)* 42, 357-364, 1987
120. BARZAGHI, N., GATTI, G., CREMA, F., MONTELEONE, M., AMIONE, C., LEONE, L. and PERUCCA, E. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. *Brit. J. Clin. Pharmacol. (London)* 24, 836-838, 1987
121. SASSO, E., PERUCCA, E. and CALZETTI, S. Double-blind comparison of primidone and phenobarbital in essential tremor. *Neurology (Minneapolis)* 38: 808-810, 1988
122. COSI, V., CALLIECO, R., GALIMBERTI, C.A., MANNI, R., TARTARA, A., LANZI, G., BALOTTIN, U. and PERUCCA, E. Effect of vigabatrin (gamma-vinyl-GABA) on visual, brainstem auditory and somatosensory evoked potentials in epileptic patients. *Eur. Neurol. (Basel)* 28, 42-46, 1988
123. PISANI, F., FAZIO, A., OTERI, G., SPINA, E., PERUCCA, E. and BERTILSSON, L. Effect of valpromide on the pharmacokinetics of carbamazepine-10,11-epoxide. *Brit. J. Clin. Pharmacol. (London)* 25: 611-613, 1988
124. PERUCCA, E., GRIMALDI, R., FRIGO, G.M., SARDI, A., MONIG, H., OHNHAUS, E.E. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. *Eur. J. Clin. Pharmacol. (Heidelberg)* 34: 595-599, 1988
125. BARZAGHI, N., GATTI, G., CREMA, F., FAJA, A., MONTELEONE, M., AMIONE, C., LEONE, L. and PERUCCA, E. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. *Int. J. Clin. Pharmacol. Res. (Geneva)* 8, 101-105, 1988
126. MANNI, R., GALIMBERTI, C.A., ZUCCA, C., PARIETTI, L., IUDICE, A., PERUCCA, E. and TARTARA, A. Efficacia e tollerabilita' a lungo termine del vigabatrin in soggetti con epilessia "resistente". *Boll. Lega It. Epil. (Milano)* 64, 159-160, 1988
127. BARZAGHI, N., MONTELEONE, M., AMIONE, C., LECCHINI, S., PERUCCA, E. and FRIGO, G.M. Lack of effect of cholestyramine on phenytoin bioavailability. *J. Clin. Pharmacol. (Hagerstown)* 28, 1112-1114, 1988
128. PAGANI, I., BARZAGHI, N., CREMA, F., PERUCCA, E., EGO, D. and ROVEI, V. Pharmacokinetics of dextromoramide in surgical patients. *Fundam. Clin. Pharmacol. (Paris)* 3: 27-35, 1989
129. BARZAGHI, N., GATTI, G., CREMA, F. and PERUCCA, E.. Impaired bioavailability of

- famotidine given concurrently with a potent antacid. *J. Clin. Pharmacol.* (Hagerstown) 29: 670-672, 1989
130. PERUCCA, E., PISANI, F., SPINA, E., OTERI, G., FAZIO, A. and BERTILSSON, L. Effects of valpromide and viloxazine on the elimination of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. *Pharmacol. Res. (New York)* 21, 11-112, 1989
131. TARTARA, A., MANNI, R., GALIMBERTI, C.A., MUMFORD, J.P., IUDICE, A. and PERUCCA, E.. Vigabatrin in the treatment of epilepsy: A long-term follow-up study. *J. Neurol. Neurosurg. Psych. (London)* 52: 467-471, 1989
132. COSI, V., CALLIECO, R., GALIMBERTI, C.A., MANNI, R., TARTARA, A., MUMFORD, J. and PERUCCA, E. Effects of vigabatrin on evoked potentials in epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 27, 61S-68S, 1989
133. BARZAGHI, N., CREMA, F., MESCOLI, G. and PERUCCA, E. Effects on cimetidine bioavailability of metoclopramide and antacids given two hours apart. *Eur. J. Clin. Pharmacol. (Heidelberg)* 37: 409-410, 1989
134. BARZAGHI, N., GATTI, G., MANNI, R., GALIMBERTI, C.A., ZUCCA, C., TARTARA, A. and PERUCCA, E. Time-dependent pharmacodynamic effects of phenobarbital in humans. *Ther. Drug Monit. (New York)* 11: 661-666, 1989
135. PERUCCA, E. Il monitoraggio dei livelli plasmatici dei farmaci. *Giorn. It. Patol. Clin. (Firenze)* 4, 359-365, 1989
136. BARZAGHI, N. and PERUCCA, E. The clinical pharmacology of carbamazepine. *J. Liga Bras. Epilepsia (Curitiba)* 2: 95-100, 1989
137. GATTI, G., BARZAGHI, N., ATTARDO-PARRINELLO, G., VITIELLO, B. and PERUCCA, E. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. *Int. J. Clin. Pharmacol. Res. (Geneva)* 9, 385-389, 1989
138. BARZAGHI, N., LEONE, L., MONTELEONE, M., TOMASINI, G. and PERUCCA, E. Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects. *Eur. J. Drug Metab. Pharmacok. (Geneva)* 14, 293-298, 1989
139. PISANI, F., PERUCCA, E. and DI PERRI, R. Clinically relevant antiepileptic drug interactions. *J. Int. Med. Res. (Cambridge)* 18: 1-15, 1990
140. BIALER, M., HAJ-YEHIA, A., BARZAGHI, N., PISANI, F. and PERUCCA, E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. *Eur. J. Clin. Pharmacol. (Heidelberg)* 38: 289-291, 1990
141. MARTINES, C., BARZAGHI, N. and PERUCCA, E. Farmacologia clinica do valproato de sodio (acido valproico). *J. Liga Bras. Epilepsia (Curitiba)* 3: 31-35, 1990
142. MARTINES, C., BARZAGHI, N. and PERUCCA, E. Farmacologia clinica da fenitoina. *J. Liga Bras. Epilepsia (Curitiba)* 3, 3-9, 1990
143. PISANI, F., CAPUTO, M., FAZIO, A., OTERI, G., RUSSO, M., SPINA, E., PERUCCA, E. and BERTILSSON, L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of

- carbamazepine, with valproic acid: A pharmacokinetic study. *Epilepsia (New York)* 31, 339-342, 1990
144. PERUCCA, E. and CALZETTI, S. La farmacologia clinica del tremore essenziale. *Basi Raz. Ter. (Padova)* 20, 373-385, 1990
145. PERUCCA, E. Il monitoraggio terapeutico dei farmaci nella pratica routinaria. Verso la terza fase: l'utilizzo razionale. *Giorn. It. Chim. Clin. (Padova)* 15, 159-162, 1990
146. SASSO, E., PERUCCA, E., FAVA, R. and CALZETTI, S. Primidone in the long-term treatment of essential tremor: A prospective study with computerized quantitative analysis. *Clinical Neuropharmacology (New York)* 13: 67-76, 1990
147. ANGELERI, F., SCARPINO, O., AVANZINI, G., BINELLI, D., BARUZZI, A., PROCACCIANTI, G., BERGAMASCO, B., BIANCO, C., CANGER, R., MAI, R., DI PERRI, R., PISANI, F., LOEB, C., COCITO, L., MANFREDI M., FAEDDA, M.T., MUTANI, R., GIANELLI, M., TARTARA, A., PERUCCA, E., TASSINARI, C.A., MICHELUCCI, R., ZAPPOLI, R., ZACCARA, G. and IUDICE, A. Studio multicentrico con vigabatrin nell'epilessia farmaco-resistente. *Boll. Lega It. Epil. (Milano)* 70/71, 121-123, 1990
148. MARTINES, C., GATTI, G., SASSO, E., CALZETTI, S. and PERUCCA, E. The disposition of primidone in elderly patients. *Brit. J. Clin. Pharmacol. (London)* 30, 607-611, 1990
149. BARZAGHI, N., CREMA, F., GATTI, G., PIFFERI, G. and PERUCCA, E. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. *Eur. J. Drug Metab. Pharmacok (Geneva)* 15, 333-338, 1990
150. FAZIO, A., PERUCCA, E. and PISANI, F. Liquid chromatographic analysis of antiepileptic drugs: An overview. *J. Liq. Chromat. (New York)* 13, 3711-3740, 1990
151. SASSO, E., PERUCCA, E., FAVA, R. and CALZETTI, S. Quantitative comparison of barbiturates in essential hand and head tremor. *Movement Disorders (New York)* 6:65-68, 1991
152. BARZAGHI, N., GATTI, G., CREMA, F. and PERUCCA, E. Protective effect of cyanidin (IdB 1027) against aspirin-induced fall in gastric transmucosal potential difference in normal subjects. *Ital. J. Gastroenterol. (Roma)* 23: 249-252, 1991
153. CLINICAL PHARMACOLOGY AND TOXICOLOGY STUDY GROUP, ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY (Coordinator: E. PERUCCA). Interlaboratory variability in drug assay: a comparison of quality control data with re-analysis of routinary patient samples. I. Anticonvulsant drugs and theophylline. *Ther. Drug Monit. (New York)* 13:131-139, 1991
154. CLINICAL PHARMACOLOGY AND TOXICOLOGY STUDY GROUP ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY (Coordinator: E. PERUCCA). Interlaboratory variability in drug assay: a comparison of quality control data with re-analysis of routinary patient samples. II. Digoxin. *Ther. Drug Monit. (New York)* 13:141-145, 1991
155. PERUCCA, E. Farmacocinetica degli anticonvulsivanti nell'anziano. *Basi Raz. Ter. (Padova)* 21:147-150, 1991
156. BARZAGHI, N., GATTI, G., MANNI, R., GALIMBERTI, C.A., ZUCCA, C., PERUCCA, E., and TARTARA, A. Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers. *Eur. J. Drug Metab. Pharmacok. (Geneva)* 16:81-87, 1991

157. TARTARA, A., GALIMBERTI, C.A., MANNI, R., PARIETTI, L., ZUCCA, C., BAASCH, H., CARESIA, L., MUCK, W., BARZAGHI, N., GATTI, G. and PERUCCA, E. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients. *Brit. J. Clin. Pharmacol. (London)* 32: 335-340, 1991
158. MANNI, R., RATTI, M.T., GALIMBERTI, C.A., PERUCCA, E., ZUCCA, C., MORINI, R., PARIETTI, L. and TARTARA, A. Valutazione clinico-neurofisiologica della sonnolenza diurna in pazienti con epilessia in monoterapia. *Boll. Lega It. Epil. (Milano)* 74, 45-46, 1991
159. MANNI, R., RATTI, M.T., BARZAGHI N., GALIMBERTI, C.A., ZUCCA, C., PERUCCA, E., and TARTARA, A. Daytime sleepiness in healthy university students: A multiparametric study. *It. J. Neurol. Sci. (Milano)* 12, 303-309, 1991
160. PERUCCA, E. La metodologia per la valutazione clinica dei nuovi farmaci antiepilettici: I dati dell'esperienza. *Boll. Lega It. Epil. (Milano)* 75/76, 53-57, 1991
161. SASSO, E., PERUCCA, E., NEGROTTI, A. and CALZETTI, S. Acute tolerance to the tremorolytic effect of primidone. *Neurology (Minneapolis, U.S.A.)* 41, 602-603, 1991
162. PERUCCA, E. Routes of drug administration. *Medicine International (Oxford)* 101, 4229-4234, 1992
163. PISANI, F., FAZIO, A., ARTESI, C., RUSSO, M., TRIO, R., OTERI, G., PERUCCA, E. and DI PERRI, R. Elevation of plasma phenytoin by viloxazine in epileptic patients: A clinically significant drug interaction. *J. Neurol. Neurosurg. Psych. (London)* 55, 126-127, 1992
164. TARTARA, A., MANNI, R., GALIMBERTI, C.A., MORINI, R., MUMFORD, J.P., IUDICE, A. and PERUCCA, E. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. *Acta Neurol. Scand. (Copenhagen)* 86, 247-251, 1992
165. TONINI, M., GATTI, G., MANZO, L., OLIBET G., COCCINI, T., PERUCCA, E. Vigabatrin does not affect the intestinal absorption of phenytoin in rat duodeno-jejunal loops in situ. *Pharmacol. Res. (London)* 26, 201-205, 1992
166. SCHANDALIK R., GATTI, G. and PERUCCA, E. Pharmacokinetics of silybin in bile following administration of IdB 1016 and silymarin in cholecystectomy patients. *Arznm. Forsch. (Heidelberg)* 42, 964-968, 1992
167. PISANI, F., FAZIO, A., ARTESI, C., OTERI, G., SPINA, E., TOMSON, T. and PERUCCA, E. Impairment of carbamazepine-10,11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. *Brit. J. Clin. Pharmacol. (London)* 34, 85-87, 1992
168. GATTI, G., BARZAGHI, N., ACUTO, G., ABBIATI, G., FOSSATI, T. and PERUCCA, E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glyceryl-phosphorylcholine and citicoline in normal volunteers. *Int. J. Clin. Pharmacol. Ther. Toxicol. (Munche)* 30, 331-335, 1992
169. MANNI, R., RATTI, M.T., GALIMBERTI, C.A., PERUCCA, E. and TARTARA, A. Sonnolenza diurna e funzioni psicomotorie in soggetti con epilessia in terapia cronica con fenobarbitale o valproato. *Boll. Lega It. Epil. (Milano)* 79/80, 285-286, 1992

170. PERUCCA, E. La terapia farmacologica delle epilessie. *Leader for Chemist (Milano)* 3 (7):12-19, 1992
171. LOEB C., IUDICE A., PERUCCA, E., GNANASAKHATHY, A. (Italian Study Group on Vigabatrin). Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy. *Ital. J. Neurol. Sci (Milano)* 13:1-16, 1992
172. PERUCCA, E. Il vigabatrin: Un nuovo farmaco per il trattamento dell'epilessia. *Hospital Management (Milano)* 119, 19-27, 1993
173. PERUCCA, E. Pharmacokinetics of anti-epilepsy drugs in neonates, infants and children. *Epilog (Abingdon)* 4, 7-10, 1993
174. SPINA, E., POLLICINO, A.M., AVENOSO, A., CAMPO, G.M., PERUCCA, E. and CAPUTI, A.P. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. *Ther. Drug Monit.* 15, 243-246, 1993
175. PISANI, F., DI PERRI, R., PERUCCA, E., RICHENS, A. Interaction of lamotrigine with sodium valproate. *The Lancet (London)* 341, 1224, 1993
176. PERUCCA, E. The clinical pharmacology of the new antiepileptic drugs. *Pharmacol. Res. (London)* 28, 89-106, 1993
177. PERUCCA, E. Drug interactions with nimesulide. *Drugs (Auckland)* 46 (suppl. 1), 79-82, 1993
178. GATTI, G., BARZAGHI, N., DOMINIJANNI R., CORDARO C.I. and PERUCCA, E. Enantioselective effects of levodropropizine and dropropizine on psychomotor functions in normal volunteers: A placebo controlled, double-blind comparative study. *Drugs Expl. Clin. Res. (Geneva)* 19, 33-39, 1993
179. MANNI, R., RATTI, M.T., PERUCCA, E., GALIMBERTI, C.A. and TARTARA, A. A multiparametric investigation of daytime sleepiness and psychomotor functions in epileptic patients treated with phenobarbital and sodium valproate: A comparative controlled study. *EEG Clin. Neurophysiol. (Amsterdam)* 86, 322-328, 1993
180. TARTARA, A., GALIMBERTI, C.A., MANNI R., MORINI, R., LIMIDO, G., GATTI, G., BARTOLI, A., STRADA, G. and PERUCCA, E. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. *Brit. J. Clin. Pharmacol. (London)* 36, 366-368, 1993
181. PERUCCA, E. and RICCIARDI, L. Farmacologia dell'epilessia e sport: effetti neurologici e cardiovascolari dei farmaci antiepilettici. *Boll. Lega It. Epil. (Milano)* 84, 21-22, 1993
182. PISANI, F., HAJ-YEHIA, A., FAZIO, A., ARTESI, C., OTERI G., PERUCCA, E., KROETZ, D.L., LEVY, R.H. and BIALER, M. Pharmacokinetics of valnoctamide in epileptic patients and its interaction with carbamazepine: Inc vitro/in vivo correlation. *Epilepsia (New York)* 34, 954-959, 1993
183. PATRINI, C., PERUCCA, E., REGGIANI, C. and RINDI, G. Effects of phenytoin on the in vivo kinetics of thiamine and its phosphoesters in rat nervous tissue. *Brain Res. (Amsterdam)* 628, 179-186, 1993
184. PERUCCA, E. and XIAODONG, S. Interazioni neuropsico-farmacologiche nell'epilessia. *Boll.*

185. GATTI, G., BARTOLI, A., MARCHISELLI R., MICHELUCCI, R., TASSINARI, C.A., PISANI, F., ZACCARA, G., TIMMINGS, P., RICHENS, A. and PERUCCA, E. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. *Brit. J. Clin. Pharmacol. (London)* 36, 603-606, 1993
186. BARTOLI, A., GATTI, G., CHIMIENTI, M., CORBELLINI, D. and PERUCCA, E. Does lidocaine affect oxidative dextromethorphan metabolism "in vivo"? *Giorn. It. Chim. Clin. (Padova)* 18, 125-129, 1993
187. MANNI, R., GALIMBERTI, C.A., RATTI, M.T., BONI, S., PERUCCA, E. and TARTARA, A. Sonnolenza diurna in soggetti con epilessia in monoterapia cronica: Dati MSLT e di performance psicomotoria. *Boll. Lega It. Epil. (Milano)* 82/83, 167-168, 1993
188. PERUCCA, E. Il ruolo del vigabatrin nel trattamento delle epilessie. *Farmaci* 17 (Suppl. 3/4), 1-8, 1993
189. PERUCCA, E., CONCIA, E. and CRUCIANI M. Ketoprofen penetration into suction skin blister fluid: A comparison of two topical formulations of ketoprofen lysine. *Advances in Therapy (New York)* 10:86-94, 1993
190. SCHANDALIK, R. and PERUCCA, E. Pharmacokinetics of silipide in patients with extrahepatic biliary obstruction. *Drugs Exp. Clin. Res. (Geneva)* 20, 37-42, 1994
191. XIAODONG, S., GATTI, G., BARTOLI, A., CIPOLLA, G., CREMA, F., PERUCCA, E. Omeprazole does not enhance the metabolism of phenacetin, a marker of cytochrome P450 activity, in healthy volunteers. *Ther. Drug Monit. (New York)* 16, 248-250, 1994
192. CORASANNITI, T., GATTI, G., CREMA, F., ATTARDO-PARRINELLO, G., BARZAGHI, N., PERUCCA, E. The disposition of theophylline in patients with lung and breast cancer. *Drugs Expl. Clin. Res. (Geneva)* 20, 115-120, 1994
193. SPINA, E., AVENOSO, A., CAMPO, G.M., CAPUTI, A.P. and PERUCCA, E. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. *Ther. Drug Monit. (New York)* 16, 432-434, 1994
194. PERUCCA, E., GATTI, G. and SPINA, E. Clinical pharmacokinetics of fluvoxamine. *Clinical Pharmacokinetics (Auckland)* 27, 175-190, 1994
195. PERUCCA, E. Monotherapy is still best practice. *Int. Epilepsy News (Haarlem)* 117, 11-13, 1994 (articolo pubblicato sulla medesima rivista anche in lingua giapponese)
196. PERUCCA, E. Il vigabatrin nella terapia dell'epilessia. *Contatto Farmacia (Roma)* 2 (suppl) 1-4, 1994
197. GATTI, G., BARTOLI, A., BERTIN, D., STROLIN-BENEDETTI, M. and PERUCCA, E. Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafragel, a novel inhibitor of thromboxane synthase, in normal volunteers. *Eur. J. clin. Pharmacol. (Heidelberg)* 47, 275-280, 1994
198. GATTI, G. and PERUCCA, E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. *Int. J. Clin.*

199. SPINA, E., CAMPO, G.M., AVENOSO, A., CAPUTI, A.P., ZUCCARO, P., PACIFICI, R., GATTI, G., STRADA, G., BARTOLI, A. and PERUCCA, E. CYP2D6-related oxidation polymorphism in Italy. *Pharmacol Res. (London)* 29, 281-289, 1994

200. SPINA, E. and PERUCCA, E. Newer and older antidepressants. A comparative review of drug interactions. *CNS Drugs (Auckland)* 2:479-497, 1994

201. PISANI, F., FAZIO, A., OTERI, G., ARTESI, C., XIAO, B., PERUCCA, E. and DI PERRI, R. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. *Acta Neurol. Scand. (Copenhagen)* 90, 130-132, 1994

202. PISANI, F., XIAO, B., FAZIO, A., SPINA, E., PERUCCA, E. and TOMSON, T. Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. *Epilepsy Research (Amsterdam)* 19, 245-248, 1994

203. PERUCCA, E., GATTI, G., CIPOLLA, G., SPINA, E., BAREL, S., SOBACK, S., GIPS, M. and BIALER, M. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. *Clin. Pharmacol. Ther. (St. Louis)* 56, 471-476, 1994

204. BARTOLI, A., GATTI, G. and PERUCCA, E. Metodiche per la valutazione dell'attivita' dei sistemi enzimatici ossidativi implicati nel metabolismo dei farmaci: Significato clinico e aspetti tecnici. *Giorn. It. Chim. Clin. (Padova)* 19,97-109, 1994

205. PERUCCA, E. Monitoraggio terapeutico dei farmaci: Utilizzazione razionale e ruolo del farmacologo clinico. *Basi Raz. Ter. (Padova)* 24, 169-170, 1994

206. SPINA, E., AVENOSO, A., CAMPO, G.M., CAPUTI, A.P. and PERUCCA, E. The effect of carbamazepine on the 2-hydroxylation of desipramine. *Psychopharmacology (Heidelberg)* 117, 413-416, 1995

207. BEGHI, E. and PERUCCA, E. The management of epilepsy in the 1990s. Acquisitions, uncertainties and perspectives for future research. *Drugs (Auckland)* 49, 680-694, 1995

208. PERUCCA, E. Pharmacological problems in the management of epilepsy in children. *Seizure (London)* 4, 139-143, 1995

209. PERUCCA, E. Pharmacological principles as a basis for polytherapy. *Acta Neurol. Scand. (Copenhagen)* 162 (suppl), 31-34, 1995

210. PERUCCA, E. Il rapporto costo-beneficio nel monitoraggio terapeutico dei farmaci. *Farmeconomia (Milano)* 2, 38-45, 1995

211. PIFFERI G. and PERUCCA, E. The cost benefit ratio of enantiomeric drugs. *Eur. J. Drug Metab. Pharmacok. (Geneva)* 20, 15-25, 1995

212. PERUCCA, E. Choice of drugs in adult epilepsies. *Int. Epilepsy News (Haarlem)* 119, 14-15, 1995

213. PERUCCA, E. Treatment strategies in suboptimally controlled epilepsy - Role of combination therapy. *Ictal (London)* 12, 10-14, 1995

214. STABLES, J., BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., LOISEAU, P. and PERUCCA, E. Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. *Epilepsy Res. (Amsterdam)* 22:235-246, 1995
215. GUERRINI, R. and PERUCCA, E. A medical overview highlights advances. *Int. Epilepsy News (Haarlem)* 122, 8-10, 1995
216. PERUCCA E. Il valproato di sodio nel trattamento delle epilessie parziali dell'adulto: I risultati dell'esperienza internazionale. *Boll. Lega It. Epil. (Milano)* 91/92 (suppl 1), 11-14, 1995
217. PERUCCA, E., POITOU, P. and PIFFERI, G. Comparative pharmacokinetics and bioavailability of two oral formulations of thicocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers. *Eur. J. Drug Metab. Pharmacok. (Geneva)* 20, 301-305, 1995
218. GIACCONE, M., BARTOLI, A, GATTI, G., MARCHISELLI, R. PISANI, F. and PERUCCA, E. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. *Brit. J. clin. Pharmacol. (London)* 41, 575-579, 1996
219. SPINA, E., AVENOSO, A., CAMPO, G.M., CAPUTI, A.P. and PERUCCA, E. Phenobarbital induces the CYP2D6-mediated 2-hydroxylation of desipramine. *Ther. Drug Monit. (New York)* 18, 60-64, 1996
220. MARCHIONI, E., PERUCCA, E., SORAGNA, D., BO, P., MALASPINA, A., FERRANDI, D, ALBERGATI, A. and SAVOLDI, F. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. *Neurology (Minneapolis)* 46, 853, 1996
221. PERUCCA, E. and BIALER, M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on Topiramate, zonisamide and tiagabine. *Clinical Pharmacokinetics (Auckland)* 31, 29-46, 1996
222. BARTOLI, A., XIAODONG, S., CIPOLLA, G., MARCHISELLI, R., GATTI, G. and PERUCCA, E. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. *Ther. Drug Monit.* 18, 586-591, 1996
223. PERUCCA, E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. *Epilepsia (New York)* 37 (suppl 2):8-13, 1996
224. SPINA, E., PISANI, F. and PERUCCA, E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. *Clinical Pharmacokinetics (Auckland)* 31: 198-214, 1996
225. MICHELUCCI, R., CIPOLLA, G., PASSARELLI, D., GATTI, G., OCHAN, M., HEINIG, R., TASSINARI, C.A. and PERUCCA, E. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. *Epilepsia (New York)* 37, 1107-1110, 1996
226. BIALER, M., JOHANNESSEN, KUPFERBERG, H.J., S.I., LEVY, R.H., LOISEAU, P. and PERUCCA, E. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. *Epilepsy Res. (Amsterdam)* 25, 299-319, 1996
227. CANGER, R., AVANZINI, G., TARTARA, A., DURISOTTI, C., GUIDOLIN, L., BINELLI S., CANAFOGLIA, L., SARTORI, L., GAROFALO, P., DI FAZIO, M., CICOGNA, C., BERTELLETTI, D. and PERUCCA, E. Efficacia e tollerabilita' di topiramato in terapia add-on: Analisi ad interim di uno

studio aperto policentrico. *Boll. Lega It. Epil. (Milano)* 95/96, 251-253, 1996

228. PERUCCA, E. The new generation of antiepileptic drugs: Advantages and disadvantages. *Brit. J. clin. Pharmacol. (London)* 42, 531-543, 1996

229. TARTARA, A., SARTORI, I., MANNI, R., GALIMBERTI, C.A., DI FAZIO, M. and PERUCCA, E. Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial. *Ital. J. Neurol. Sci. (Milano)* 17, 429-432, 1996

230. RIZZO, V., MEMMI, M., MORATTI, R., MELZI D'ERIL G. and PERUCCA, E. Concentrations of L-dopa in plasma and plasma ultrafiltrates. *J. Pharm. Biomed. Anal. (Amsterdam)* 14, 103-146, 1996

231. SPINA, E., GITTO, C., AVENOSO, A., CAMPO, G.M., CAPUTI, A.P and PERUCCA, E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response: A prospective study. *Eur. J. clin. Pharmacol. (Heidelberg)* 51, 395-398, 1997

232. SPINA, E., AVENOSO, A., CAMPO, G.M., SCORDO, M.G., CAPUTI, A. and PERUCCA, E. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. *Brit. J. clin. Pharmacol. (London)* 43, 315-318, 1997

233. BARTOLI, A., GATTI, G., CIPOLLA, G., BARZAGHI, N., VELIZ, G., FATTORE, C., MUMFORD, J. and PERUCCA, E. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. *Epilepsia (New York)* 38, 702-707, 1997

234. BAREL, S., YAGEN, B., SCHURIG, V., SOBACK, S., PISANI, F., PERUCCA, E. and BIALER, M. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. *Clin. Pharmacol. Ther. (St. Louis)* 61, 442-449, 1997

235. PERUCCA, E. A pharmacological and clinical review of topiramate, a new antiepileptic drug. *Pharmacol. Res. (London)* 35, 241-256, 1997

236. AVENOSO, A., SPINA, E., CAMPO, G., FACCIOLA, G., FERLITO, M., ZUCCARO, P., PERUCCA, E. and CAPUTI, A.P. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications. *Pharmacol. Res. (London)* 35, 335-339, 1997

237. PERUCCA, E. A multicentre, randomized prospective trial comparing add-on therapy with alternative monotherapy in patients with partial seizures refractory to initial treatment. *Giorn. It. Farm. Clin.* 11, 41-49, 1997

238. PERUCCA, E. Evaluation of drug treatment outcome in epilepsy: A clinical perspective. *Pharmacy World Science (Amsterdam)* 19, 217-222, 1997

239. BARTOLI, A., GUERRINI, R., BELMONTE, A., ALESSANDRI, M.G., GATTI, G. and PERUCCA, E. The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: A prospective study with preliminary assessment of correlations with clinical response. *Ther. Drug Monit. (New York)* 19, 252-260, 1997

240. SPINA, E., ARENA, D., SCORDO, M.G., FAZIO, A., PISANI, F. and PERUCCA, E. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. *Ther. Drug Monit. (New York)* 19, 535-538, 1997

241. CANGER, R., AVANZINI, G., TARTARA, A., DURISOTTI, C., GUIDOLIN, L., BINELLI, S., CANAFOGLIA, L., SARTORI, I., GAROFALO, P., POZZI, F., SILENZI, V., BERTELLETTI, D., DI FAZIO, M. and PERUCCA, E. Efficacia e tollerabilità del topiramato nella terapia aggiuntiva a lungo termine: Analisi ad interim dopo quattro anni di trattamento. *Boll. Lega It. Epil (Milano)* 99, 105-107, 1997
242. PERUCCA, E., MARCHIONI, E., SORAGNA, D. and SAVOLDI, F. Fluoxetine-induced movement disorders and deficient CYP2D6 enzyme activity. *Movement Disorders (New York)* 12, 624-626, 1997
243. PERUCCA, E. Pharmacologic advantages of antiepileptic drug monotherapy. *Epilepsia (New York)* 38 (suppl 5), 6-8, 1997
244. BIALER, M., LEVY R.H. and PERUCCA, E. Does carbamazepine have a narrow therapeutic plasma concentration range? *Ther .Drug Monit. (New York)* 20, 56-59, 1998
245. BAKER, G.A., CAMFIELD, C., CAMFIELD, P., CRAMER, J.A., ELGER, C.E., JOHNSON, A.L., MARTINS DA SILVA, A., MEINARDI, H., MUNARI, C., PERUCCA, E. and THORBECKE, R M. Commission on Outcome Measurement in Epilepsy, 1994-1997: Final report. *Epilepsia (New York)* 39, 213-231, 1998
246. GUERRINI, R., BELMONTE, A., CAMPICCHI, R., CASALINI, C. and PERUCCA, E. Reversible pseudo-atrophy of the brain and mental deterioration associated with valproate treatment. *Epilepsia (New York)* 39, 27-32, 1998
247. ZUCCARO, P., PACIFICI, R., ALTIERI, I, AVENOSO, A., PELLEGRINI, M., SPINA, E., PERUCCA, E. and PICHINI, S. Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. *Ther Drug Monit. (New York)* 20, 20-24, 1998
248. PERUCCA, E, GRAM, L., AVANZINI, G. and DULAC, O. Antiepileptic drugs as a cause of worsening of seizures. *Epilepsia (New York)* 39, 5-17, 1998
249. PERUCCA, E. Innovative monotherapy trial designs for the assessment of antiepileptic drugs: A critical appraisal. *Eur. J. clin. Pharmacol. (Heidelberg)* 54, 1-6, 1998
250. MARCHIONI, E., PERUCCA, E., SORAGNA, D., SAVOLDI, F. Su un caso di sindrome coreica indotta dal trattamento con fluoxetina. *Rend. Ist. Lomb. Scienze Lett. B. (Milano)* 129, 283-287, 1995 (pubbl. 1998)
251. GATTI, G., FATTORE C., LEONE, L. and PERUCCA, E. I nuovi farmaci antiepilettici: Aspetti farmacologici e clinici. *Ligand Assay (Milano)* 3, 30-40, 1998
252. PERUCCA, E. Monothérapie et nouveaux antiépileptiques. *Neurologies (Paris)* 2, 23-25, 1998
253. PERUCCA, E. Antiepileptic drug interactions. *Neurol. Reviews International (London)* 2, 13-15, 1998
254. PERUCCA E. Pharmacoresistance in epilepsy. How should it be defined? *CNS Drugs (Auckland)* 10, 171-179, 1998
255. GATTI, G., FATTORE, C. and PERUCCA, E. The new antiepileptic drugs: From the laboratory

to the clinic. *Epilepsi (Istanbul)* 4, 6-17, 1998

256. SPINA, E., AVENOSO, A., FACCIOLA, G., FRABBRAZZO, M., MONTELEONE, P., MAJ, M., PERUCCA, E. and CAPUTI, A.P. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. *Int. Clin. Psychopharmacol. (New York)* 13, 141-145, 1998

257. FATTORE, C., CIPOLLA, G., GATTI, G., BARTOLI, A., ORTICELLI, G., PICOLLO, R., MILLERIOUX, L., CIOTTOLI, G.B. and PERUCCA, E. Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers. *Clin. Drug. Invest. (Auckland)* 16, 387-392, 1998

258. BALDY-MOULINIER, M, COVANIS, A., D'URSO, C., ESKAZAN, E., FATTORE, C., GATTI, G., HERRANZ, J.L., IBRAHIM, S., KHALIFA, A., MRABET, A., NEUFELDT, M. and PERUCCA, E. Therapeutic strategies against epilepsy in Mediterranean countries: A report from an international collaborative survey. *Seizures. (London)* 7, 513-520, 1998

259. XIAO DONG, S., ZHI PING, Z., ZHONG XIAO, W., CHONG SHU, C., BARTOLI, A, GATTI, G., D'URSO, S. and PERUCCA, E. The effect of active and passive smoke on CYP1A2-mediated phenacetin metabolism in Chinese subjects. *Ther. Drug Monit. (New York)* 20, 371-375, 1998

260. FACCIOLA, G., AVENOSO, A., SPINA, E. and PERUCCA, E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. *Ther. Drug Monit. (New York)* 20, 628-630, 1998

261. PERUCCA, E., TOMSON, T. Monotherapy trials with the new antiepileptic drugs: Study designs, practical relevance and ethical implications. *Epilepsy Res (Amsterdam)* 33, 247-262, 1999

262. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., LOISEAU, P. and PERUCCA, E. Progress report on new antiepileptic drugs: A summary of the Fourth Eilat Conference. *Epilepsy Res. (Amsterdam)* 34, 1-41, 1999

263. PERUCCA, E. The treatment of epilepsy in pregnancy. *Epilog (Abingdon)* 17, 2-4, 1999

264. FACCIOLA, G., AVENOSO, A., SCORDO, M.G., MADIA, A.G., VENTIMIGLIA, A., PERUCCA, E. and SPINA, E. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. *Ther. Drug Monit. (New York)* 21, 341-345, 1999

265. FATTORE, C., CIPOLLA, G., GATTI, G., D'URSO, S., LIMIDO, G.L., STURM, Y., BERNASCONI, C. and PERUCCA, E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. *Epilepsia (New York)* 40, 783-787, 1999

266. PISANI, F., OTERI, G., RUSSO, DI PERRI, R., PERUCCA, E. and RICHENS, A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction. *Epilepsia (New York)* 40, 1141-1146, 1999

267. XIAO DONG, S., ZHI PING, Z., ZHONG XIAO, W., CHONG SHU, C., BARTOLI, A, GATTI, G., D'URSO, S. and PERUCCA, E. Possible enhancement of the first-pass metabolism of phenacetin by grape juice in Chinese subjects. *Brit. J. clin. Pharmacol. (London)* 48, 638-640, 1999

268. PERUCCA, E. The spectrum of the new antiepileptic drugs. *Acta Neurologica Belgica*

269. PERUCCA, E. A prospective study on the effects of antiepileptic drugs on the human fetus: The European Registry initiative. *Epileptologia (Warsaw)* 7, 269-276, 1999 (in Polish)

270. PERUCCA, E. The clinical pharmacokinetics of the new antiepileptic drugs. *Epilepsia (New York)* 40 (Suppl. 9), 7-13, 1999

271. VOLOSOV, A., XIAODONG, S., PERUCCA, E., YAGEN, B., SINTOV, A. and BIALER, M. Enantioselective pharmacokinetics of 10-hydroxycarbamazepine after oral administration of oxcarbazepine to healthy Chinese subjects. *Clin. Pharmacol Ther. (St. Louis)* 66, 547-553, 1999

272. GUERRINI, R., BELMONTE, A., PARMEGGIANI, L. and PERUCCA, E. Myoclonic status epilepticus following high-dosage lamotrigine therapy. *Brain Developm. (Amsterdam)* 21, 420-424, 1999

273. TARTARA, A., GALIMBERTI, C.A., SARTORI, I., VERSINO, M., POLITINI, L., MANNI, R. and PERUCCA, E. Alterazioni del campo visivo in soggetti con epilessia in trattamento cronico con vigabatrin. *Boll. Lega It. Epil. (Milano)* 106/107, 189-190, 1999

274. BINELLI, S., CANAFOGLIA, L., MAMOLI, D., AVANZINI, G., GUIDOLIN, L., CANGER, R., POLITINI, L., SARTORI, I., TARTARA, A., PERUCCA, E., GIUBERGIA, S., et al. Felbamato come terapia aggiuntiva nelle epilessie parziali farmacoresistenti dell'adulto. *Boll. Lega It. Epil. (Milano)* 106/107, 317-318, 1999

275. GALIMBERTI, C.A., ZANOTTA, N., SARTORI, I., MANNI, R., PERUCCA, E. and TARTARA, A., Epilessia nell'anziano: Dati dai registri di un centro neurologico. *Boll. Lega It. Epil. (Milano)* 106/107, 177-179, 1999

276. BONOMI, I., JANNUZZI, G. and PERUCCA, E. Quando due farmaci sono meglio di uno? *Boll. Lega It. Epil. (Milano)* 106/107, 333-335, 1999

277. PERUCCA, E. Neuropsychiatric therapies. *EACPT Third Congress. Idrugs (London)* 2, 1269-1270, 1999

278. JANNUZZI G., CIAN, P., FATTORE, C., GATTI, G., BARTOLI, A., MONACO, F. and PERUCCA, E. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. *Epilepsia (New York)* 41, 222-230, 2000

279. GATTI, G., BONOMI, I., JANNUZZI, G. and PERUCCA, E. The new antiepileptic drugs: Pharmacological and clinical aspects. *Current Pharm Design. (Hilversum)* 6, 839-860, 2000

280. VOLOSOV, A., BIALER, M., XIAODONG, S., PERUCCA, E., SINTOV, A., and YAGEN, B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbamazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. *J. Chromatogr. B (Amsterdam)* 738, 419-425, 2000

281. PERUCCA, E. Is there a role for therapeutic drug monitoring of new anticonvulsants? *Clin. Pharmacokin. (Auckland)* 38, 191-204, 2000

282. SPINA, E., AVENOSO, A., FACCIOLA, G., SCORDO, M.G., ANCIONE, M., MADIA, A.G., VENTIMIGLIA, A. and PERUCCA, E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional

283. AVANZINI, G., BATTINO, D. and PERUCCA, E. Offspring of mothers with epilepsy. *International Epilepsy News* (Heemstede) 138, 10-11, 2000
284. SPINA, E., AVENOSO, A., FACCIOLA, G., SALEMI, M., SCORDO, M.G., GIACOBELLO, T., MADIA, A.G. and PERUCCA, E. Plasma concentrations of risperidone and 9-hydroxy-risperidone: Effect of comedication with carbamazepine or valproate. *Ther. Drug Monit.* (New York) 22, 481-485, 2000
285. SCHMIDT, D., GRAM, L., KRAMER, G., PERUCCA, E., KALVIAINEN, R. and ELGER, C.E. Tiagabine in the treatment of epilepsy. A clinical review with a guide for the prescribing physician. *Epilepsy Res* (Amsterdam) 41, 245-251, 2000
286. PERUCCA, E., BEGHI, E., SHORVON, S. and TOMSON, T. Assessing risk to benefit ratio in antiepileptic drug therapy. *Epilepsy Res.* (Amsterdam) 41, 107-139, 2000
287. PARMEGGIANI, L., BELMONTE, A., FERRARI, A.R., PERUCCA, E. and GUERRINI, R. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: An open, prospective, long-term study. *J. Child. Neurol.* 15, 671-674, 2000
288. HEANEY, D.C., SHORVON, S.D., SANDER, J.W., BOON, P., KOMAREK, V., MARUSIC, P., DRAVET, C., PERUCCA, E., MAJKOWSKI, J., LIMA, J.L., ARROYO, S., TOMSON, T., RIED, S., VAN DONSELAAR, C., ESKAZAN, E., PEETERS, P., CARITA, P., TJONG-A-HUNG, I., MYON, E. and TAIEB, C. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. *Epilepsia*, 41 (suppl. 5), S37-S44, 2000
289. PICCINELLI, P., BORGATTI, R., PERUCCA, E., TOFANI, A., DONATI, G. and BALOTTIN, U. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. *Epilepsia* (New York) 41, 1485-1488, 2000
290. PERUCCA, E. New antiepileptic drugs: Fifth Eilat Conference. *IDrugs* (London) 3, 1149-1153, 2000
291. FATTORE, C. and PERUCCA, E. La qualità scientifica nel IV Congresso Europeo di Epilettologia: Risultati delle procedure di valutazione. *Boll. Lega It. Epil.* (Milano), 110, 23-26, 2000
292. SPINA, E., AVENOSO, A., FACCIOLA, G., SALEMI, M., SCORDO, M.G., ANCIONE, M., MADIA, A.G. and PERUCCA, E. Relationship between plasma risperidone and 9-hydroxy-risperidone concentrations and clinical response in patients with schizophrenia. *Psychopharmacology* (Berlin) 153, 238-243, 2001
293. SPINA, E., SCORDO, G., AVENOSO, A. and PERUCCA, E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. *J clin Psychopharmacol* (New York) 21, 108-109, 2001
294. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., LOISEAU, P. and PERUCCA, E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). *Epilepsy Res.* (Amsterdam) 43, 11-58, 2001
295. BATTINO, D., CROCI, D., GRANATA, T., MAMOLI, D., MESSINA, S. and PERUCCA, E. Single-dose pharmacokinetics of lamotrigine in children: Influence of age and antiepileptic comedication. *Ther. Drug Monit.* (New York) 23, 217-222, 2001
296. PERUCCA, E. Trial duration and follow-up. *Epilepsy Res.* (Amsterdam) 45, 123-127, 2001
297. PERUCCA, E. Trials in women. *Epilepsy res.* (Amsterdam), 45, 147, 2001
298. PERUCCA, E. and RICHENS, A. Trials in the elderly. *Epilepsy Res.* (Amsterdam) 45, 149-151, 2001
299. PERUCCA, E., DULAC, O., SHORVON S. and TOMSON T. Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimisation. *CNS Drugs* (Auckland) 15, 609-621, 2001
300. SPINA, E. and PERUCCA, E. Antiepilettici: interazioni farmacologiche a livello epatico. *Facts, News and Views* (Milano) 2, 12-17, 2001
301. PERUCCA, E. The management of refractory idiopathic epilepsies. *Epilepsia* (Philadelphia) 42

(Suppl. 3), 31-35, 2001

302. GENTON, P., GUERRINI, R. and PERUCCA, E. Tiagabine in clinical practice. *Epilepsia (New York)* 42 (suppl. 3), 42-45, 2001
303. PERUCCA, E., ARROYO, S., BALDY-MOULINIER, M., DULAC, O., ESKASAN, E., HALASZ, P., KRAMER, G., MAJKOWSKI, J., NIKRONOVA, M., TOMSON, T. and JOHANNESSEN, S. ILAE Commission Report: Evaluations and Awards at the 4th European Congress of Epileptology, Florence, 2-12 October 2000. *Epilepsia (New York)* 42, 1366-1368, 2001
304. PERUCCA, E. Seizures provoked by antiepileptic drugs and by other medications. *Neurologia (Barcelona)* 16 (suppl. 2), 43-51, 2001
305. PERUCCA, E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. *Fund. Clin Pharmacol. (Paris)* 15, 405-417, 2001
306. STEFAN, H., HALASZ, P., GIL-NAGEL, A., SHORVON, S., BAUER, G., BEN-MENACHEM, E., PERUCCA, E., WIESER, H.G. and STEINLEIN, O. Recent advances in the diagnosis and treatment of epilepsy. *Eur. J. Neurol. (Berlin)* 8, 519-539, 2001
307. PERUCCA, E. What can we learn from clinical trials of anticonvulsant drugs in epilepsy? *Eur. J. Pain (London)*, 5 (suppl A), 35-44, 2002
308. PERUCCA, E. Industria farmaceutica e sperimentatori clinici: Alleanze e conflitti di interesse. *Epilepsy News (Milano)* 1, 2-5, 2002
309. PERUCCA, E. Marketed new antiepileptic drugs: Are they better than old generation agents? *Ther. Drug Monit. (New York)* 24, 74-80, 2002
310. DE SANTIS, A., VILLANI, R., SINISI, M., STOCCHETTI, N. and PERUCCA, E. Add-on phenytoin fails to prevent early seizures following surgery for supratentorial brain tumors: A randomized controlled study. *Epilepsia (New York)* 43, 175-182, 2002
311. SPINA, E. and PERUCCA, E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. *Epilepsia (New York)* 43 (suppl. 2), 37-44, 2002
312. GATTI, G. and PERUCCA, E. Challenges in the pharmacotherapy of the epilepsies. *Expert Rev Neurother. (London)* 2, 439-442, 2002
313. BATTINO, D., MAMOLI, D., MESSINA, S. PERUCCA, E., TOMSON, T. Malformaciones en lo hijos de embarazadas con epilepsia. Presentación de un registro internacional de fármacos antiepilepticos y embarazo (EURAP). *Rev Neurol. (Barcelona)* 34, 476-480, 2002
314. PERUCCA, E. Terapia farmacologica: Editoriale. *Epilepsy Highlights (Torino)* 2, 1-2, 2002
315. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., LOISEAU, P. and PERUCCA, E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). *Epilepsy Res. (Amsterdam)* 51, 1-31, 2002
316. PERUCCA E. Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. *CNS Drugs (Auckland)* 16, 695-714, 2002
317. SPINA, E., AVENOSO, A., SCORDO, M.G., ANCIONE, M., MADIA, A., GATTI, G. and PERUCCA, E. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. *J. Clin. Psychopharmacol. (New York)* 22, 419-423, 2002
318. MAMOLI, D., MESSINA, S. and PERUCCA, E. Assessing relative risks of fetal malformations following prenatal exposure to old and new antiepileptic drugs: The international Eurap pregnancy registry initiative. *Acta Neurologica Taiwanica (Taipei)* 11, 114-119, 2002
319. JANNUZZI, G., GATTI, G., MAGNI, P., SPINA, E., PACIFICI, R., ZUCCARO, P.G., TORTA, R., GUARNERI, L. and PERUCCA, E. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: Sources of variability and preliminary observations on relations with clinical response. *Ther. Drug Monit (New York)* 24, 616-627, 2002
320. PERUCCA, E. Antiepileptic Drugs and seizure aggravation. *AES Direct (New York)* 2, 23-24, 2002
321. PERUCCA, E and ARZIMANOGLU, A. Improving epilepsy for life. *Epileptic Disorders (Montrouge)* 4 (Suppl. 2), 7-8, 2002
322. TALLIS, R., BOON, P., PERUCCA, E and STEPHENS, L.. Epilepsy in the elderly:

- Management issues. *Epileptic Disorders* (Montrouge) 4 (Suppl. 2), 33-40, 2002
323. PERUCCA, E. Overtreatment in epilepsy: Adverse consequences and mechanisms. *Epilepsy Research* (Amsterdam) 52, 25-33, 2002
324. PERUCCA, E. Role of therapeutic drug monitoring in epilepsy. *Hospital Pharmacy Europe* (London) 6, 37-39, 2002
325. GATTI, G., FERRARI, A.R., GUERRINI, R., BONANNI, P., BONOMI, I. and PERUCCA, E. Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. *Ther. Drug Monit* (New York) 25, 54-60, 2003
326. GATTI, G., BONOMI, I., MARCHISELLI, R., FATTORE, G., SPINA, E., SCORDO, G., PACIFICI, R. and PERUCCA, E. Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. *J Chromatogr. B* (Amsterdam) 784, 375-383, 2003
327. WILLIAMS J., BIALER M., JOHANNESSEN S.I., KRAMER, G., LEVY, R., MATTSON, R.H., PERUCCA, E., PATSALOS, P.N. and WILSON J.F. Interlaboratory variability in the quantification of new generation antiepileptic drugs based upon external quality assessment data. *Epilepsia* (Oxford) 44, 40-45, 2003
328. PERUCCA, E., GIDAL B.E. and BALTES, E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: A pooled analysis of data from randomised adjunctive therapy trials. *Epilepsy Res.* (Amsterdam) 53, 47-56, 2003
329. BRITZI M, SOBACK, S., ISOHERRANEN, N., LEVY, R.H., PERUCCA, E. DOOSE, D.R., MARYANOFF, B.E. and BIALER, M. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. *Ther. Drug Monit.* (Philadelphia) 25, 314-322, 2003
330. PATSALOS, P.N. and PERUCCA, E. Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs. *The Lancet Neurology* (London) 2, 347-356, 2003
331. BATTINO, D. CROCI, D., ROSSINI, A., MESSINA, S., MAMOLI D. and PERUCCA E. Serum carbamazepine concentrations in elderly patients: A case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. *Epilepsia* (Oxford) 44, 923-929, 2003
332. PERUCCA, E. Current trends in antiepileptic drug therapy. *Epilepsia* (Oxford) 44 (Suppl 4), 41-47, 2003
333. PERUCCA, E., JOHANNESSEN S.I. The ideal pharmacokinetic properties of an antiepileptic drug: How close does levetiracetam come? *Epileptic Disorders* (Paris) 5 (Suppl. 1), 17-26, 2003
334. ARROYO, S. and PERUCCA, E. Translating monotherapy trials into clinical practice: A look into the abyss. *Epilepsy and Behaviour* (Amsterdam) 4, 457-463, 2003
335. PATSALOS, P.N. and PERUCCA, E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. *The Lancet Neurology* (London) 2, 473-481, 2003
336. SANDER J.W. and PERUCCA, E. Epilepsy and comorbidity: Infections and antimicrobials usage in relation to epilepsy management. *Acta. Neurol. Scand.* (Copenhagen) 108 (suppl. 180), 1-7, 2003
337. FERRARI, A.R., GUERRINI, R., GATTI, G., ALESSANDRI M.G., BONANNI, P., and PERUCCA, E. Influence of dosage, age and comedication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. *Ther. Drug Monit.* (Philadelphia), 25, 700-708, 2003
338. BEGHI E, GATTI, G., TONINI, C., BEN-MENACHEM, E., CHADWICK, D., NIKANOROVA, M., GROMOV, S., SMITH, P.E.M., SPECCHIO, L.M., PERUCCA E. on behalf on the BASE Study Group. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: A multicentre, randomized, pragmatic, controlled trial. *Epilepsy Res.* (Amsterdam) 57, 1-13, 2003
339. GALIMBERTI, C.A., ARBASINO, C., MARCHIONI, E. and PERUCCA, E. La prognosi

- dellepilessia a esordio senile nel paziente anziano ambulatoriale. *Boll Lega It Epil (Milano)* 121/122, 33-34, 2003
340. GIL-NAGEL, A., PERUCCA, E., GARCIA-MORALES, I., ARROYO, S. and SERRATOSA, J.M. Evaluations and awards at the fifth European Congress of epileptology, Madrid, 6-10 October 2002. *Epilepsia* 45, 396-398, 2004
341. PERUCCA, E. NICE guidance on newer drugs for epilepsy in adults. *Brit Med J (London)*, 328, 1273-1274, 2004
342. BATTINO, D., CROCI, D., MAMOLI, D., MESSINA, S. and PERUCCA E. Influence of aging on serum phenytoin concentrations: A pharmacokinetic analysis based on therapeutic drug monitoring data. *Epilepsy Res. (Amsterdam)* 59, 155-165, 2004
343. TOMSON, T., PERUCCA, E., and BATTINO, D. Navigating toward foetal and maternal health: The challenge of treating epilepsy in pregnancy. *Epilepsia* 45, 1171-1175, 2004
344. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG, H.J., LEVY, R.H., P., PERUCCA, E. and TOMSON, T. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). *Epilepsy Res. (Amsterdam)* 61, 1-48, 2004
345. PERUCCA, E. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. *Commentary. Br J Clin Pharmacol.* 58, S864-865, 2004
346. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., SABERS, A., VAJDA, F., and the COLLABORATIVE EURAP STUDY GROUP. EURAP: An international registry of antiepileptic drugs and pregnancy. *Epilepsia (Oxford)* 45, 1463-1464, 2004
347. DAMBROSIO, R. and PERUCCA, E. Epilepsy after head injury. *Curr. Opin. Neurol. (Philadelphia)* 17:731-735, 2004
348. KALE, R. and PERUCCA, E. Revisiting phenobarbital for epilepsy. *Brit Med. J (London)* 329, 1199-1200, 2004
349. BRITZI, M, PERUCCA, E., SOBACK, S., LEVY, R.H., FATTORE, C., CREMA, F., GATTI, G., DOOSE, D.R., MARYANOFF, B.E, and BIALER, M.. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. *Epilepsia (Oxford)* 46, 378-384, 2005
350. PERUCCA, E. Pregabalin. *CNS Drugs (Auckland)* 19, 273-274, 2005
351. MESSINA, S., BATTINO, D. CROCI, D., RATTI, S. and PERUCCA E. Phenobarbital pharmacokinetics in old age: A case-matched evaluation based on therapeutic drug monitoring data. *Epilepsia (Oxford)* 46, 372-377, 2005
352. PERUCCA E. An introduction to antiepileptic drugs. *Epilepsia (Oxford)* 46 (suppl 4), 31-37, 2005
353. BATTINO, D. CROCI, D., ROSSINI, A., MESSINA, S., MAMOLI D. and PERUCCA E. Topiramate pharmacokinetics in children and adults with epilepsy: A case-matched comparison based on therapeutic drug monitoring data. *Clinical Pharmacokinetics (Auckland)* 44, 407-416, 2005
354. GIDAL, B., BALTES, E., OTOUL, C. and PERUCCA, E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. *Epilepsy Res. (Amsterdam)* 64, 1-11, 2005
355. DORIT, M. SPECCHIO, L.M., BRITZI, M., PERUCCA, E., SPECCHIO, N., LA NEVE, A., SOBACK, S., LEVY, R.H., GATTI, G., DOOSE, D.R., MARYANOFF, B.E, and BIALER, M.. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetic and metabolic profile of topiramate at steady state in patients with epilepsy. *Epilepsia (Oxford)* 46, 1046-1054, 2005
356. PERUCCA, E. Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. *Epileptic Disorders (Paris)* 7 (suppl. 1), S1-S8, 2005
357. PERUCCA, E. Birth defects after prenatal exposure to antiepileptic drugs. *Lancet Neurology (London)* 4, 781-786, 2005
358. SCORDO M.G., SPINA, E., DAHL, M.L., GATTI, G. and PERUCCA, E., Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. *Basic Clin Pharmacol Toxicol.* 97, 296-301, 2005

359. PERUCCA, E. Introduction. *Acta Neurol. Scand. (Copenhagen)* 112, (Suppl. 181), 3, 2005
360. PERUCCA, E., MEADOR, K.J. Adverse effects of antiepileptic drugs. *Acta Neurol. Scand. (Copenhagen)* 112, (Suppl. 181), 31-35, 2005
361. PERUCCA, E. and KWAN, P. Overtreatment in epilepsy: How does it occur and how it can be avoided. *CNS Drugs (Auckland)* 19, 897-908, 2005
362. PERUCCA, E. Aggravation of seizures by antiepileptic drugs. *Zh Nevrol Psikhiatr Im S S Korsakova (Moscow)* 105, 61-64, 2005 (in Russian)
363. PERUCCA, E. Pharmacokinetic variability of new antiepileptic drugs at different ages. *Ther. Drug Monit (New York)* 27, 714-717, 2005
364. AVANTAGGIATO, P., VEGGIOTTI, P., MARCHIONI, E., ALFEI, E. and PERUCCA, E. Fattori predittivi di farmacoresistenza nelle epilessie in età valutativa: Studio su un campione di 159 pazienti. *Boll. Lega It. Epil. (Milano)* 129/130, 99-100, 2005
365. PERUCCA, E. Pharmacotherapy of epilepsy in women. *Zh Nevrol Psikhiatr Im S S Korsakova (Moscow)* 105,60-62, 2005 (in Russian)
366. PERUCCA, E., BERLOWITZ, D., BIRNBAUM, A., CLOYD, J.C., GARRARD, J., HANLON, J.T., LEVY, R.H. and PUGH M.J. Pharmacological and clinical aspects of antiepileptic drugs use in the elderly. *Epilepsy Res. (Amsterdam)* 68 (suppl. 1), 49-63, 2006
367. THE EURAP STUDY GROUP (Central Project Committee: BATTINO, D., BONIZZONI, E., CRAIG, J., PERUCCA, E., SABERS, A., LINDHOUT, D., PERUCCA, E, TOMSON, T., and VAJDA, F.). Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry. *Neurology* 66, 354-360, 2006
368. PERUCCA, E. Active control trials: Endpoints beyond conventional efficacy and tolerability measures. *Epilepsy Res. (Amsterdam)* 68, 73-74, 2006
369. STEFAN, H., LOPES DA SILVA, F.H., LOSCHER, W., SCHMIDT, D., PERUCCA, E., BRODIE, M.J., BOON, P.A., THEODORE, W.H. and MOSHE, S.L. Epileptogenesis and rational therapeutic strategies. *Acta Neurol Scand. (Copenhagen)* 113, 139-155, 2006
370. MAZZUCHELLI, I., ONAT, F.Y., OZKARA, C., ATAKLI, D., SPECCHIO, L.M., LA NEVE, A., GATTI, G., and PERUCCA, E. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. *Epilepsia (Oxford)* 47, 504-509, 2006
371. PERUCCA E. Clinically relevant drug interactions with antiepileptic drugs. *Brit. J. clin. Pharmacol.(Oxford)* 61, 246-255, 2006
372. FREEMAN, J., VEGGIOTTI, P., LANZI, G., TAGLIABUE, A., and PERUCCA, E. The ketogenic diet: From molecular mechanisms to clinical effects. *Epilepsy Res.(Amsterdam)* 68, 145-180, 2006
373. PERUCCA, E. Clinical pharmacokinetics of new generation antiepileptic drugs at the extremes of age. *Clinical Pharmacokinetics (Auckland)* 45, 351-363, 2006
374. PERUCCA, E and TOMSON, T. Prenatal exposure to antiepileptic drugs. *The Lancet (London)* 367, 1467-1469, 2006
375. PERUCCA, E., ALDENKAMP, A. , TALLIS, R., and KRAMER, G. Role of valproate across the ages. Treatment of epilepsy in the elderly. *Acta Neurol. Scand (Copenhagen)* 114 (suppl 184): 28-40, 2006
376. PERUCCA E. Difficulties to demonstrate efficacy of anti-ictal drugs in clinical trials. *Epilepsy Res (Amsterdam)* 69, 188-190, 2006
377. FATTORE, C., MESSINA, S., BATTINO, D., CROCI, D., MAMOLI, D. and PERUCCA, E. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady state: A case-matched evaluation based on therapeutic drug monitoring data. *Epilepsy Res. (Amsterdam)* 70, 153-160, 2006
378. PERUCCA, E. Retigabine in partial seizures. A viewpoint. *CNS Drugs* 20, 609-610, 2006
379. LEPPIK, I.E., DE RUE, K., EDRICH, P., and PERUCCA, E. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: The levetiracetam experience. *Epileptic Disorders (Paris)* 8, 118-130, 2006
380. GLAUSER, T., BEN-MENACHEM, E., BOURGEOIS, B., CNAAN, A., CHADWICK, D., GUERREIRO, C., KALVIAINEN, R., MATTSON, R., PERUCCA, E and TOMSON, T. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as

- initial monotherapy for epileptic seizures and syndromes. *Epilepsia (Oxford)* 47, 1094-1120, 2006
381. GALIMBERTI, C.A., MAZZUCHELLI, I., ARBASINO, C., CANEVINI, M.P., FATTORE, C., PERUCCA, E. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. *Epilepsia (Oxford)* 47, 1569-1572, 2006
382. SPINA, E., D'ARRIGO, C., MIGLIARDI, G., SANTORO, V. MUSCATELLO, M.R., MICO, U., D'AMICO, G. and PERUCCA, E. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. *Ther Drug Monit. (Philadelphia)* 28, 599-602, 2006
383. MINICUCCI, F., MUSCAS, G., PERUCCA, E., CAPOVILLA, G., VIGEVANO, F. and TINUPER, P. Treatment of status epilepticus in adults: Guidelines of the Italian League against Epilepsy. *Epilepsia (Oxford)* 46 (suppl. 5):16-20, 2006
384. PERUCCA, E., ALBANI, F., CAPOVILLA, G., DALLA BERNARDINA, B., MICHELUCCI, R., and ZACCARA, G. Recommendations of the Italian League against Epilepsy Working Group on Generic Products of Antiepileptic Drugs. *Epilepsia (Oxford)* 46 (suppl. 5):16-20, 2006
385. GUERRINI, R., CANEVINI, M.P., MICHELUCCI, R. and PERUCCA, E. Preface. *Epilepsia (Oxford)* 46 (suppl. 5):1, 2006
386. BIALER, M., JOHANNESSEN, S.I., KUPFERBERG H.J., LEVY, R.H., PERUCCA, E. and TOMSON, T. Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). *Epilepsy Res. (Amsterdam)* 73, 1-52, 2007
387. BRODIE, M.J., PERUCCA, E., RYVLIN, P., BEN-MENACHEM, E., MEENCKE H.J., FOR THE LEVETIRACETAM MONOTHERAPY STUDY GROUP. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. *Neurology (Minneapolis)* 68, 402-408, 2007
388. PERUCCA E. Age-related changes in pharmacokinetics: predictability and assessment methods. *Int. Rev. Neurobiol. (Amsterdam)* 81, 183-99, 2007
389. MANENT, J.B., JORQUERA, I., MAZZUCHELLI, I., DEPAULIS, A., PERUCCA, E., BEN-ARI, Y. and REPRESA, A. Foetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. *Epilepsia (Oxford)* 48, 684-693, 2007
390. PERUCCA, E. Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? *Nat Clin Pract Neurol. (London)* 3 :194-195, 2007
391. HUSSAIN, H.M. and PERUCCA, E. Hormone replacement therapy in women with epilepsy. *Epilepsia (Oxford)* 48, 1030-1031, 2007
392. PERUCCA, E. Treatment of epilepsy in developing countries. *Brit Med J (London)* 334, 1175-1176, 2007
393. SAETRE, E., PERUCCA, E., ISOJARVI, J. and GJERSTAD, L., on behalf of the LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. *Epilepsia (Oxford)* 48, 1292-1302, 2007
394. ZACCARA, G., FRANCIOTTA, D. and PERUCCA, E. Idiosyncratic adverse reactions to antiepileptic drugs. *Epilepsia (Oxford)* 48, 1223-1244, 2007
395. PERUCCA, E., ALEXANDRE, V. Jr. and TOMSON T. Old versus new antiepileptic drugs: The SANAD study. *The Lancet (London)* 370, 313, 2007
396. FRANCO, V., MAZZUCHELLI, I., FATTORE, C., MARCHISELLI, R., GATTI, G. and PERUCCA, E. Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 854, 63-67, 2007
397. MAZZUCHELLI, I., FRANCO, V., FATTORE, C., MARCHISELLI, R., PERUCCA, E. and GATTI G. A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. *Ther Drug Monit (Philadelphia)* 29, 319-324, 2007
398. WILD, J.M., AHN, H., BAULAC, M., BURSZTYN, J., CHIRON, C., GANDOLFO, E., SAFRAN, A.B., SCHIEFER, U. and PERUCCA, E. Vigabatrin and epilepsy. Lessons learned. *Epilepsia (Oxford)* 48, 1318-1327, 2007

399. PERUCCA E. Adverse drug interactions in epilepsy. *Neurology Asia (Kuala Lumpur)* 12 (Suppl. 1), 21-24, 2007
400. PERUCCA, E., FRENCH, J. and BIALER, M. Development of new antiepileptic drugs: Challenges, incentives, and recent advances. *Lancet Neurol. (London)* 6, 793-804, 2007
401. PERUCCA, E. Changes in plasma levetiracetam concentrations in pregnant women and their breastfed infants. *Nat Clin Pract Neurol. (London)* 3, 538-539, 2007
402. PENNELL, P., GIDAL, B., SABERS, A., GORDON, J., and PERUCCA, E. for the INTERNATIONAL AED PHARMACOLOGY GROUP FOR THE HEALTH OUTCOMES IN PREGNANCY AND EPILEPSY FORUM. Pharmacology of antiepileptic drugs during pregnancy and lactation. *Epilepsy Behav (Amsterdam)* 11, 263-269, 2007
403. AGUGLIA, U., BARBONI, G., BATTINO, D., CAVAZZUTI, G.B., CITERNESI, A., COROSU, R., GUZZETTA, F.M., IANNETTI, P., MAMOLI, D., PATELLA, A., PAVONE, L., PERUCCA, E., PRIMIERO, F., PRUNA, D., SAVASTA, S., SPECCHIO, L.M. and VERROTTI, A. Conferenza di consenso su gravidanza, parto, puerperio ed epilessia. *Lega Italiana contro l'Epilessia. Boll Lega It Epil (Milano)* 135, 9-32, 2007
404. PERUCCA, E., ALBANI, F., CAPOVILLA, G., DALLA BERNARDINA, B., MICHELUCCI, R., and ZACCARA, G. Raccomandazioni del gruppo di studio LICE in merito all'utilizzo di prodotti generici di farmaci antiepilettici. *Boll Lega It Epil (Milano)* 135, 33-39, 2007
405. MINICUCCI, F., MUSCAS, G., PERUCCA, E., CAPOVILLA, G., VIGEVANO, F. and TINUPER, P. Trattamento dello stato epilettico nell'adulto. *Boll Lega It Epil (Milano)* 135, 49-59, 2007
406. PERUCCA, E. The treatment of the first seizure: The risks. *Epilepsia (Oxford)* 49 (suppl. 1), 29-34, 2008
407. MANENT, J.B., JORQUERA, I., FRANCO, V., BEN-ARI, Y., PERUCCA, E., and REPRESA, A. Antiepileptic drugs and brain maturation: Fetal exposure to lamotrigine generates cortical malformations in rats. *Epilepsy Res. (Amsterdam)* 78, 131-139, 2008
408. PATSALOS, P.N., BERRY, D.J., BOURGEOIS, B.F.D., CLOYD, J.C., GLAUSER, T.A., JOHANNESSEN, S.I., LEPIK, I., TOMSON, T. and PERUCCA, E. Antiepileptic Drugs Best Practice Guidelines for Therapeutic Drug Monitoring: A Position Paper by the Subcommittee on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia (Oxford)* 49, 1239-1276, 2008
409. PERUCCA, E., CLOYD, J., CRITCHLEY, D. and FUSEAU, E. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. *Epilepsia (Oxford)* 49, 1123-1141, 2008
410. PERUCCA, E. Equivalenti nelle sotto-popolazioni fragili: Il punto di vista del farmacologo. *Boll Inf Farm (Roma)* 3/08, 118-120, 2008
411. MEADOR, K.J., PENNELL, P.B., HARDEN, C.L., GORDON, J.C., TOMSPN, T., KAPLAN; P.W., HOLMES, G.L., FRENCH, J.A., HAUSER, W.A. WELLS, P.G., CRAMER J.A. and HOPE WORK GROUP (ARAOJO, R., BAKER, G., BATTINO, D., BEN-MENACHEM, E., BERG, A., CNAAN, T., COHEN, M., CONWAY, J., DRUZIN, M., FEIBUS, K., GAILY, E., GALE, K., GIDAL, B., CILLIAM, F., GRANT, D., HESDORFFER, D., HOLMES, L., LIPORACE, J., MORROW, J., NORWITZ, E., PERUCCA, E., PORTMAN, D., ROBERT-GNANSIA, E., ROBINSON, J., SABERS, A., SCHEURLE, A., THURMAN, D., VAJDA, F., WESTFIELD, M., and WIDE, K). Pregnancy registries in epilepsy: a consensus statement on health outcomes. *Neurology (Minneapolis)* 71, 1109-1117, 2008
412. PERUCCA, E. Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions. *CNS Drugs (Auckland)* 22, 917-938, 2008
413. PERUCCA, E. L'off-label: Dall'ambito normativo alla strategia di registrazione. *Boll Lega It Epil (Milano)* 138/139 (Suppl. 1), 25-30, 2008
414. PERUCCA, E., YASOTHAN, U., CLINCKE, G. and KIRKPATRICK, P. Lacosamide. *Nature Reviews Drug Discovery (London)* 7, 973-974, 2008
415. RYVLIN, P., PERUCCA, E., and RHEIMS, S. Pregabalin for the management of partial epilepsy. *Neuropsychiatr Dis Treat* 4:1211-1224, 2008
416. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE H.S.

- Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). *Epilepsy Res. (Amsterdam)* 83, 1-43, 2009
417. ARZIMANOGLU, A., FRENCH, J., BLUME, W.T., CROSS, J.H., ERNST, J.P., FEUCHT, M., GENTON, P., GUERRINI, R., KLUGER, G., PELLOCK, J.M., PERUCCA, E. and WHEELLES J.W. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. *Lancet Neurology (London)* 8, 82-93, 2009
418. PERUCCA, E. and TOMSON, T. Epilepsy: seizures, syndromes and survival. *Lancet Neurology (London)* 8, 10-12, 2009
419. AGUGLIA, U., BARBONI, G., BATTINO, D., CAVAZZUTI, G.B., CITERNESI, A., COROSU, R., GUZZETTA, F.M., IANNETTI, P., MAMOLI, D., PATELLA, A., PAVONE, L., PERUCCA, E., PRIMIERO, F., PRUNA, D., SAVASTA, S., SPECCHIO, L.M. and VERROTTI, A. Italian Consensus Conference on epilepsy and pregnancy, labor and puerperium. *Epilepsia (Oxford)* 50 (suppl 1), 7-23, 2009
420. SAETRE, E., ABDELNOOR, M., AMLIE, J.P., TOSSEBRO, M., PERUCCA, E., TAUBOLL, E., ANFINSEN, O.G., ISOJARVI, J. and GJERSTAD, L. Cardiac function and antiepileptic drug treatment in the elderly: A comparison between lamotrigine and sustained-release carbamazepine. *Epilepsia (Oxford)* 50, 1841-1849, 2009
421. RUSCA, A., DI STEFANO AFD, DOIG, M.V., SCARSI C., and PERUCCA, E. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid / eicosapentanoic acid after multiple dose administration in healthy volunteers. *Eur J clin Pharmacol (Amsterdam)* 65, 503-510, 2009
422. FRANCIOTTA, D., KWAN, P and PERUCCA, E. Genetics basis for idiosyncratic reactions to antiepileptic drugs. *Curr. Opin. Neurol. (Philadelphia)* 22, 144-149, 2009
423. CURIA, G., BIAGINI, G., PERUCCA, E. and AVOLI, M. Lacosamide: A new approach to target voltage-gated sodium currents in epileptic disorders. *CNS Drugs (Auckland)* 23, 555-568, 2009
424. THE EURAP STUDY GROUP (Central Project Committee: BATTINO, D., BONIZZONI, E., CRAIG, J., PERUCCA, E., SABERS, A., LINDHOUT, D., PERUCCA, E, TOMSON, T., and VAJDA, F.). Utilization of antiepileptic drugs during pregnancy: Comparative patterns in 38 countries based on data from the EURAP registry. *Epilepsia (Oxford)* 50, 2305-2309, 2009
425. WILD, J.M., CHIRON, C., AHN, H., BAULAC, M., BURSZTYN, J., GAROFALO, E., GOLDBERG, I, GONI, F.J., MERCIER, F., NORDMANN, J.P., SAFRAN, A.S., SCHIEFER, U. and PERUCCA, E. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. *CNS Drugs (Auckland)* 23, 965-982, 2009
426. RAMSAY, R.E., PERUCCA, E., ROBBINS, J., BARRETT, J.A. and SPIEGEL, K. Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. . *Epilepsia (Oxford)* 50, 1891-1898, 2009
427. KWAN, P., ARZIMANOGLU, A., BERG, A.T., BRODIE, M.J., HAUSER A.H., MATHERN, G., MOSHE, S.L., PERUCCA, E. , WIEBE, S. and FRENCH, J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia (Oxford)* 51, 1069-1077, 2010
428. ARZIMANOGLU, A., RYVLIN, P. and PERUCCA, E. When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy? *Lancet Neurol. (London)* 9, 457-459, 2010
429. SAETRE, E., ABDELNOOR, M., PERUCCA, E., TAUBOLL, E., ISOJARVI, J., and GIERSTAD, D. .Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. *Epilepsy Behav. (Amsterdam)* 17, 395-401, 2010
430. ALEXANDRE, V. Jr., CAPOVILLA, G., FATTORE, C., FRANCO, V., GAMBARDELLA, A., GUERRINI, R., LA BRIOLA, F., LADOGANA, M., ROSATI, E., SPECCHIO, L.M., STRIANO, S. and PERUCCA, E. on behalf of the SOPHIE Study Group. Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. *Epilepsia (Oxford)* 51, 921-925, 2010

431. PERUCCA, E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. *Epilepsia (Oxford)* 50 (Suppl 12), 49-50, 2010
432. PERUCCA, E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. *Epilepsy Curr. (Oxford)* 9,153-157, 2010
433. RHEIMS, S., PERUCCA, E and RYVLIN, P. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy. *Epilepsia (Oxford)*, 51, 935-936, 2010
434. CANEVINI, M.P., DE SARRO, G., GALIMBERTI, C.A., GATTI, G., LICCHETTA, L., MALERBA, A., MUSCAS, G., LANEVE, A., STRANO, P., and PERUCCA, E. on behalf of the SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. *Epilepsia (Oxford)* 51, 797-804, 2010
435. PERUCCA, E. When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. *Epilepsia (Oxford)* 51, 1933-1935, 2010
436. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE H.S. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). *Epilepsy Res. (Amsterdam)* 92, 89-124, 2010
437. MALERBA, A., CIAMPA, C., DE FAZIO, S., FATTORE, C., FRASSINE, B., LA NEVE, A., PELLACANI, S., SPECCHIO, L.M., TIBERTI, A., TINUPER, P. and PERUCCA, E. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. *Epilepsy Res (Amsterdam)* 91, 273-282, 2010
438. MOSHE, S.L., PERUCCA, E., WIEBE, S. and MATHERN, G.W. The International League Against Epilepsy at the threshold of its second century: year 1. *Epilepsia (Oxford)* 52, 185-187, 2011
439. RHEIMS, S., PERUCCA, E., CUCHERAT, M. and RYVLIN, P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. *Epilepsia (Oxford)* 52, 219-233, 2011
440. FREITAS-LIMA, P., ALEXANDRE, V., Jr., PEREIRA, L.R., FELETTI, F., PERUCCA, E., and SAKAMOTO, A.C. Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. *Epilepsy Res (Amsterdam)* 94, 117-120, 2011
441. PRUNETTI, P. and PERUCCA, E. New and forthcoming anti-epileptic drugs. *Curr Opin Neurol. (Philadelphia)* 24, 159-164, 2011
442. ALEXANDRE, V., Jr., MONTEIRO, E.A., FREITAS-LIMA, P., PINTO, K.D., VELASCO, T.R., TERRA, V.C., PINHEIRO-MARTINS, A.P., SOUZA, R.M., PERUCCA, E., and SAKAMOTO, A.C. Addressing overtreatment in patients with refractory epilepsy at a tertiary referral center in Brasil. *Epileptic Disorders (Paris)* 13, 56-60, 2011
443. CITRARO, R., SCICCHITANO, F., DE FAZIO, S., RAGGIO, R., MAINARDI, P., PERUCCA, E., DE SARRO, G. and RUSSO, E. Preclinical activity of alpha-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. *Epilepsy Research (Amsterdam)* 95, 60-69, 2011
444. FATTORE, C, BONIVER, C, CAPOVILLA, G., CERMINARA, C., CITTERIO, A., COPPOLA, G., COSTA, P., DARRA, F., VECCHI M. and PERUCCA, E. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. *Epilepsia (Oxford)* 52, 802-809, 2011
445. MANNA, I., GAMBARDELLA, A., BIANCHI, A., STRIANO, P., TOZZI, R., AGUGLIA, U., BECCARIA, F., BENNA, P., CAMPOSTRINI, R., CANEVINI, M.P., CONDINO, F, DURISOTTI, C., ELIA, M. GIALLONARDO, A.T., IUDICE, A.T., LABATE, A., LA NEVE, A., MICHELUCCI R., MUSCAS G.C., PARAVIDINO, R., ZACCARA, G., ZUCCA, C., ZARA, F. and PERUCCA, E. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. *Epilepsia (Oxford)* 52, e40-e44, 2011
446. PERUCCA, E, TOMSON T. The pharmacological treatment of epilepsy in adults. *Lancet Neurol. (London)* 10, 446-56, 2011

447. MAZZUCHELLI, I., RAPETTI, M., FATTORE, C., FRANCO, V., GATTI, G. and PERUCCA, E. Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. *Anal Bioanal Chem. (New York)* 401, 1013-1021, 2011
448. BRODIE, M., COVANIS, T., GIL NAGEL, A., LERCHE, H., PERUCCA, E., SILLS, G., WHITE, S. Antiepileptic drug therapy: Does mechanism of action matter? *Epilepsy Behav. (Amsterdam)* 21, 331-341, 2011
449. PERUCCA, E. A young woman with recurring seizures. *Neurosciences (Riyadh)* 16, 292-294, 2011
450. PERUCCA, E., ELGER, C., HALASZ, P., FALCAO, A., ALMEIDA, L., SOARES-DA-SILVA, P. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. *Eur. J. clin. Pharmacol. (Amsterdam)* 96, 132-139, 2011
451. TOMSON, T., BATTINO, D., CRAIG, J., LINDHOUT, D., SABERS, A., PERUCCA, E. and VAJDA, F. for THE EURAP STUDY GROUP. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. *Lancet Neurol. (London)* 10, 609-617, 2011
452. FATTORE, C. and PERUCCA, E. Novel medications for epilepsy. *Drugs (Auckland)* 71, 2151-2178, 2011
453. RHEIMS, S., PERUCCA, E. and RYVLIN, P. Rheims S, Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy. *Epilepsia (Oxford)* 52, 2139-2141, 2011
454. PERUCCA, E. The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? *CNS Drugs (Auckland)* 25, 907-912, 2011
455. PERUCCA, E. Why are epilepsy trials failing? *Clin Invest. (London)* 1, 1479-1485, 2011
456. TOMSON, T., BATTINO, D. and PERUCCA, E. Major birth defects after exposure to newer-generation antiepileptic drugs. *JAMA (Chicago)* 306, 826-827, 2011
457. LUONI, C., BISULLI, F., CANEVINI, M.P., DE SARRO, G., FATTORE, C., GALIMBERTI, C.A., GATTI, G., LA NEVE, A., MUSCAS, G., SPECCHIO, L.M., STRIANO, S. and PERUCCA, E. on behalf of the SOPHIE STUDY GROUP. Determinants of health-related quality of life in pharmaco-resistant epilepsy: Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. *Epilepsia (Oxford)* 52, 2181-2191, 2011
458. BAULAC, M., DE BOER, H., ELGER, C., GLYNN, M., KALVIAINEN, R., LITTLE, A., MIFSUD, J., PERUCCA, E. and PITKANEN, A. The Written Declaration on Epilepsy: An important achievement for Europe and beyond. *Seizure (Amsterdam)* 21, 75-76, 2012
459. ARIDA, R.M., SCORZA, F.A., CAVALHEIRO, E.A., PERUCCA, E. and MOSHE, S.L. Can people with epilepsy enjoy sports? *Epilepsy Res. (Amsterdam)* 98, 94-95, 2012
460. MOSHE, S.L., PERUCCA, E., WIEBE, S. and MATHERN, G.W. The International League Against Epilepsy at the threshold of its second century: Year 2. *Epilepsia (Oxford)* 53, 215-219, 2012
461. BIRBECK, G.L., FRENCH, J.A., PERUCCA, E., SIMPSON, D.M., FRAMOW H., GEORGE, J.M., OKULICZ, J.F., CLIFFORD, D.B., HACHAD, H. and LEVY, R.H. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. *Neurology (Minneapolis)* 78, 139-145, 2012
462. BIRBECK, G.L., FRENCH, J.A., PERUCCA, E., SIMPSON, D.M., FRAMOW H., GEORGE, J.M., OKULICZ, J.F., CLIFFORD, D.B., HACHAD, H. and LEVY, R.H. Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. *Epilepsia (Oxford)* 53, 207-214, 2012
463. GALANOPOULOU, A.S., BUCKMASTER, P.S., STALEY, K.J., MOSHE, S.L., PERUCCA, E., ENGEL, J., Jr., LOSCHER, W., NOEBELS, J.L., PITKANEN, A., STABLES, J., WHITE, H.S.,

- O'BRIEN, T.J. and SIMONATO, M. for THE AMERICAN EPILEPSY SOCIETY BASIC SCIENCE COMMITTEE and THE INTERNATIONAL LEAGUE AGAINST EPILEPSY WORKING GROUP ON RECOMMENDATIONS FOR PRECLINICAL EPILEPSY DRUG DISCOVERY. Identification of new epilepsy treatments. *Issues in preclinical methodology. Epilepsia (Oxford)* 53, 571-582, 2012
464. RUSSO, E., SCICCHITANO, F., CITRARO, R., AIELLO, R., CAMASTRA, G., MAINARDI, P., CHIMIRRI, S., PERUCCA, E., DONATO, G., and DE SARRO, G. Protective activity of alpha-lactalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. *Neuroscience (Amsterdam)* 226, 282-288, 2012
465. PERUCCA, E.. What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? *Epileptic Disorders (Paris)* 14, 124-131, 2013
466. OKULICZ, J.F., GRANDITS, G.A., FRENCH, J.A., PERUCCA, E., GEORGE, J.M., LANDRUM, M.L., ACOSTA, E.P. and BIRBECK, G.L. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. *Epilepsy Res* 103, 245-253, 2013
467. KRAUSS, G.L., PERUCCA, E., BEN-MENACHEM, E., KWAN, P., SHIH, J.J., SQUILLACOTE, D., YANG, H., GEE, M., SHU, J. and LARENZA, A. Perampanel, a selective, noncompetitive -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. *Epilepsia (Oxford)* 54, 126-134, 2013
468. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE H.S. Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT X1). *Epilepsy Res. (Amsterdam)* 103, 2-30, 2013
469. GLAUSER, T., BEN-MENACHEM, E., BOURGEOIS, B., CNAAN, A., GUERREIRO, C., KALVIAINEN, R., MATTSON, R., FRENCH, J.A., PERUCCA, E. and TOMSON, T. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia (Oxford)* 54:551-63, 2013
470. MOSHE, S.L. and PERUCCA, E. *Epileptic Disorders to become the educational journal of the ILAE. Epileptic Disord. (Paris)* 15, 99, 2013
471. D'AMBROSIO, R., EASTMAN, C.L., FATTORE, C. and PERUCCA, E. Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. *Expert Rev Neurother. (London)* 13, 615-625, 2013
472. BLUMCKE I., THOM. M., ARONICA, E., ARMSTRONG, D.D., BARTOLOMEI, F., BERNASCONI, A., BERNACONI, N., BIEN, C.G., CENDES, F., CORAS, R., CROSS, J.H., JACQUES, T.S., KAHANE, P., MATHERN, G.W., MIYATA, H., MOSHE, S.L., OZ, B., OZKARA, C., PERUCCA, E., SISODIYA, S., WIEBE, S. and SPREAFICO, R. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: A Task Force report from the ILAE Commission on Diagnostic Methods. *Epilepsia (Oxford)* 54, 1315-1329, 2013
473. ITALIANO, D. and PERUCCA, E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: An update. *Clin Pharmacokinet. (Auckland)* 52:627-645, 2013
474. FRENCH, J.A., WHITE, H.S., HOLMES, G.L., PRIVITERA, M.D., COLE, A.J., QUAY, E., WIEBE, S., SCHMIDT, D., PORTER, R.J., ARZIMANOGLU, A., TRINKA, E. & PERUCCA, E. Development of new treatment approaches for epilepsy: unmet needs and opportunities. *Epilepsia (Oxford)* 54 (Suppl 4), 3-12, 2013
475. BATTINO, D., TOMSON, T., BONIZZONI, E., CRAIG, J., LINDHOUT, D., SABERS, A., Perucca, E., VAJDA, F. & EURAP STUDY GROUP. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. *Epilepsia (Oxford)* 54, 1621-1627, 2013
476. PERUCCA, E. Optimizing antiepileptic drug treatment in tumoral epilepsy. *Epilepsia (Oxford)* 54 (Suppl 9), 97-104, 2013
477. PERUCCA, E. The European Declaration on epilepsy: Past, present and future. *Epilepsy and Seizure (Tokyo)* 7, 14-22, 2014
478. KRAMER, L.D., SATLIN, A., KRAUSS, G.L., FRENCH, J., PERUCCA, E., BEN-MENACHEM, E., KWAN, P., SHIH, J.J., LAURENZA, A., YANG, H., ZHU, J., & SQUILLACOTE, D. Perampanel for

- adjunctive treatment of partial-onset seizures: A pooled doseresponse analysis of phase III studies. *Epilepsia (Oxford)* 55, 423-431, 2014
479. PERUCCA, E & REYNOLDS, E.H. In memoriam: Harry Meinardi (February 20, 1932-December 20, 2013). *Epilepsia (Oxford)* 55, 1-2, 2014
480. KRAUSS, G.L., PERUCCA, E., BEN-MENACHEM, E., KWAN, P., SHI, J.J., CLEMENT, J.F., WANG, X., BACUL, M., GEE, M., ZHU, J. & SQUILLACOTE, D. Long-term safety of peramppanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. *Epilepsia (Oxford)* 55, 1058-1068, 2014
481. PERUCCA, E., BATTINO, S. & TOMSON, T. Gender issues in antiepileptic drug treatment. *Neurobiol Dis (Amsterdam)* 72, 217-223, 2014
482. RYVLIN, P., GILLIAM, F.G., NGUYEN, D.K., COLICCHIO, G., IUDICE, A., TINUPER, P., ZAMPOINI, U., AGUGLIA, U., WAGNER, L., MINOTTI, L., STEFAN, H., BOON, P., SADLER, M., BENNA, P., RAMAN, P. & PERUCCA, E. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. *Epilepsia (Oxford)* 55, 893-900, 2014
483. PERUCCA, E. Introduction to the clinical definition of epilepsy by the ILAE president. *Epilepsia (Oxford)* 55,473-474, 2014
484. FISHER, R.S., ACEVEDO, C., ARZIMANOGLU, A., BOGACZ, A., CROSS, J.H., ELGER, C.E., ENGEL, J. Jr., FORSGREN, L., FRENCH, J.A., GLYNN, M., HESDORFFER, D.C., LEE, B.I., MATHERN, G.W., MOSHÉ, S.L., PERUCCA, E., SCHEFFER, I.E., TOMSON, T., WATANABE, M. & WIEBE, S. A practical clinical definition of epilepsy. *Epilepsia (Oxford)* 55,475-482, 2014
485. PERUCCA, E., COVANIS, A. & DUA, T. Commentary: Epilepsy is a global problem. *Epilepsia (Oxford)* 55, 1326-1328, 2014
486. FRANCO, V., CANEVINI, M.P., CAPOVILLA, G., DE SARRO, G., GALIMBERTI, C.A., GATTI, G., GUERRINI, R., LA NEVE, A., ROSATI, E., SPECCHIO, L.M., STRIANO, S., TINUPER, P. & PERUCCA, E. Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: A cross-sectional drug utilization study of tertiary care centers in Italy. *CNS Drugs (Auckland)* 28, 939-949, 2014
487. ZACCARA, G. & PERUCCA, E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. *Epileptic Disord. (Paris)* 16, 409-431, 2014
488. MOSHE, S.L., PERUCCA, E., RYVLIN, P. and TOMSON, T. Epilepsy: New advances. *Lancet (London)* 385, 884-898, 2015
489. PERUCCA, E. Commentary: Why an International Epilepsy Day? *Epilepsia (Oxford)* 56, 170-171, 2015
490. GHOSH, C., HOSSAI, M., SPRIGGS, A., GHOSH, A., GRANT, G.A., MARCHI, N., PERUCCA, E. & JANIGRO, D. Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. *Epilepsia (Oxford)* 56, 439-449, 2015
491. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE, H.S. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). *Epilepsy Res. (Amsterdam)* 111, 85-141, 2015
492. FRANCO, V. & PERUCCA, E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. *Expert Opin Drug Metab Toxicol. (London)* 11, 1269-1279, 2015
493. LUONI, C., CANEVINI, M.P., CAPOVILLA, G., DE SARRO, G., GALIMBERTI, C.A., GATTI, G., GUERRINI, R., LA NEVE, A., MAZZUCHELLI, I., ROSATI, E., SPECCHIO, L.M., STRIANO, S., TINUPER, P. and PERUCCA, E on behalf of the SOPHIE STUDY GROUP. A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. *Epilepsia (Oxford)* 56, 1162-1173, 2015
494. LAL, D., PERNHORST, K., KLEIN, K.M., REIF, P., TOZZI, R., TOLIAT, M.R., WINTERER, G., NEUBAUER, B., NURNBERG, P., ROSENOW, F., BECKER, F., LERCHE, H., KUNZ, W.S., KURKI, M.I., HOFFMANN, P., BECKER, A.J., PERUCCA, E., ZARA, F., SANDER, T. and WEBER, Y.G. Extending the phenotypic spectrum of RFX1 deletions: Sporadic focal epilepsy. *Epilepsia* 56, e129-e133, 2015]
495. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E.,

- SABERS, A., THOMAS, S.V. and VAJDA, F. for THE EURAP STUDY GROUP. Dose-dependent teratogenicity of valproate in mono- and polytherapy: An observational study. *Neurology (Minneapolis)* 18, 866-872, 2015
496. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., SABERS, A., THOMAS, S.V. and VAJDA, F. for THE EURAP STUDY GROUP. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. *Neurology (Minneapolis)* 18, 580-588, 2015.
497. FRANCO, V. and PERUCCA, E. The pharmacogenomics of epilepsy. *Expert Rev Neurother (London)* 15, 1161-1170, 2015
498. COVANIS, A., GUEKHT, A., LI, S., SECCO, M., SHAKIR, R. and PERUCCA, E. From Global Campaign to Global Commitment: The World Health Assemblys Resolution on Epilepsy. *Epilepsia (Oxford)* 56, 1651-1657, 2015
499. BAULAC, M., DE BOER, H., ELGER, C., GLYNN, M., KALVIAINEN, R., LITTLE, A., MIFSUD, J., PERUCCA, E., PITKANEN, A. and RYVLIN, P. Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Europe Advocacy Task force. *Epilepsia (Oxford)* 56, 1687-1695, 2015
500. FRANCO, V., FRENCH, J.A. and PERUCCA, E. Challenges in the clinical development of new antiepileptic drugs. *Pharmacol Res. (Amsterdam)* 103, 95-104, 2015
501. MINTZER, S., FRENCH, J.A., PERUCCA, E., CRAMER, J.A., MESSENHEIMER, J.A., BLUM, D.E., ROGAWSKI, M.A. and BAULAC, M. Is a separate monotherapy indication warranted for antiepileptic drugs? *Lancet Neurol. (London)* 14, 1229-1240, 2015
502. SAURO, K.M., WIEBE, S., PERUCCA, E., FRENCH, J., DUNKLEY, C., DE MARINIS, A., KIRPATRICK, M. and JETTE', N. Developing clinical practice guidelines for epilepsy: A report from the ILAE Epilepsy Guidelines Working Group. *Epilepsia (Oxford)* 56, 1859-1869, 2015
503. BAFTIU, A., JOHANNESSEN LANDMARK, C., NIKAJ, V., NESLEIN, I.L., JOHANNESSEN, S.I. and PERUCCA, E. Availability of antiepileptic drugs across Europe. *Epilepsia (Oxford)* 56, e191-e197, 2015
504. GALIMBERTI, C.A., TARTARA, E., DISPENZA, S., MARCHESE, D., BONIZZONI, E. and PERUCCA, E. for the ENEA-P (ELDERLY NURSING HOME EPILEPSY ASSESSMENTPAVIA) STUDY GROUP. Antiepileptic drug use and epileptic seizures in nursing home residents in the Province of Pavia, Italy: A reappraisal 12 years after a first survey. *Epilepsy Res. (Amsterdam)* 119, 41-48, 2016
505. SAURO, K.M., WIEBE, S., DUNKLEY, C., JANSZKY, J., KUMLIEN, E., MOSHE, S.L., NAKASATO, N., PEDLEY, T.A., PERUCCA, E., SENTIES, H., THOMAS, S.V., WANG, Y., WILMSHURST, J. and JETTE', N. The current state of epilepsy guidelines: A systematic review. *Epilepsia (Oxford)* 57, 13-23, 2016
506. CAPOVILLA, G., KAUFMAN, K.R., PERUCCA, E., MOSHE, S.L. and ARIDA, R. Epilepsy, seizures, physical exercise, and sports: A report from the ILAE Task Force on Sports and Epilepsy *Epilepsia (Oxford)* 57, 6-12, 2016
507. TOMSON, T., BATTINO, D. and PERUCCA, E. Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug. *Lancet Neurol. (London)* 2015; 15: S1474-4422
508. REYNOLDS, E.T., COVANIS, A. and PERUCCA, E. In memoriam: Hanneke de Boer (1946-2015). *Epilepsia (Oxford)* 57, 162-163, 2016
509. PERUCCA, E. The safety of generic substitution in epilepsy. *Lancet Neurol. (London)* 15, 344-345, 2016
510. DE OLIVEIRA BALDONI, A., FREITAS-LIMA, P., DE SANTI FERREIRA, F.I., MARTINEZ, E.Z., QUEIROZ, R.H., SAKAMOTO, A.C., ALEXANDRE, V., PERUCCA, E. and PEREIRA, L.R. An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. *Clin. Exp. Pharmacol. Physiol. (Chichester)* 43, 685-689, 2016
511. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., SABERS, A., THOMAS, S.V. and VAJDA, F. for THE EURAP STUDY GROUP. Withdrawal of valproic acid treatment during pregnancy and seizure outcome: Observations from EURAP. *Epilepsia (Oxford)* 53, e173-177, 2016

512. FRANCO, V., MARCHISELLI, R., FATTORE, C., TARTARA, E., DE SARRO, G., RUSSO, E. & PERUCCA, E. Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma. *Ther Drug Monit. (Philadelphia)* 38, 744-750, 2016
513. PERUCCA, E. Message from the ILAE President. *Epilepsia Open (Oxford)* 1, 8, 2016
514. PERUCCA, E. and WIEBE, S. Not all that glitters is gold: A guide to critical interpretation of drug trials in epilepsy. *Epilepsia Open (Oxford)* 1, 1-13, 2016
515. PERUCCA, E. A tribute to Steve White. *Neurochem. Res. (Heidelberg)*, 42, 1867-1868, 2017
516. CITRARO, R., LEO, A., FRANCO, V., MARCHISELLI, R., PERUCCA, E., De SARRO, G. and RUSSO, E. Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior. *Epilepsia (Oxford)* 58, 231-238, 2017
517. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T., WHITE, H.S. and KOEPP, M.J. Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII). *Epilepsy Res.* 130:27-36, 2017
518. BIALER, M., JOHANNESSEN, S.I., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE, H.S. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). *Epilepsia (Oxford)*, 58,181-221, 2017
519. ZUBERI, S.M. and PERUCCA, E. A new classification is born. *Epilepsia (Oxford)* 58, 511, 2017
520. SCHEFFER, I.E, BERKOVIC, S., CAPOVILLA, G., CONNOLLY, M.B., FRENCH, J., GUILHOTO, L., HIRSCH, E., JAIN, S., MATHERN, G.W., MOSHE, S.L., NORDLI, D.R., PERUCCA, E., TOMSON, T., WIEBE, S., ZHANG, Y.Z. & SAMEER S.M. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia (Oxford)* 58,512-521, 2017
521. PEREZ-PALMA, E., HELBIG, I., KLEIN, K.M., ANTTILA, V., HORN, H., REINTHALER, E.M., GORMLEY, P., GANNA, A., BYRNES, A., PERNHORST, K., TOLIAT, M.R., SAARENTAUS, E., HOWRIGAN, D.P., HOFFMAN, P., MIQUEL, J.F., DE FERRARI, G.V., NURNBERG, P., LERCHE, H., ZIMPRICH, F., NEUBAUER, B.A., BECKER, A.J., ROSENOW, F., PERUCCA E., ZARA, F., WEBER, Y.G. & LAI, LAL, D. Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsies. *J Med Genet. (London)* 54, 598-606, 2017
522. SABERS, A., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., TOMSON, T., THOMAS, S.V. & VAJDA, F. Maternal and fetal outcomes associated with vagus nerve stimulation during pregnancy. *Epilepsy Res. (Amsterdam)* 137:159-162, 2017
523. PERUCCA E. Cannabinoids in the treatment of epilepsy: Hard evidence at last? *J Epilepsy Res. (Seoul)* 7, 61-67, 2017
524. FRANCO, V., BARUFFI, K., GATTI, G., MRCHISELLI, R., FATTORE, C., CANEVINI, M.P., CREMA, F. & PERUCCA, E. A simple and rapid HPLC-UV method for the determination of retigabine in human plasma. *Biomed Chromatogr. (Oxford)* 2018; 32(5):e4168
525. BEGHI, E., CAPOVILLA, G., FRANZONI, E., MINICUCCI, F., ROMEO, A., VERROTTI, A., VIGEVANO, F. & PERUCCA, E. Midazolam vs diazepam in prolonged seizures in children: A pharmacoeconomic approach. *Acta Neurol. Scand. (Copenhagen)* 37, 24-28, 2018
526. GUERRINI, R. & PERUCCA, E. Genetic testing to prevent adverse reactions to antiepileptic drugs: Primum non nocere. *Neurology (Minneapolis)* 90, 155-156, 2018
527. HELMSTAEDTER, C., BEGHI, E., ELGER, C.E., KALVIAINEN, R., MALMGREN, K., MAY, T.W., PERUCCA, E. TRINKA, E. & WITT, J.A. No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk-An analysis of Finnish health register and German health insurance data. *Epilepsia (Oxford)* 59,1303-1306, 2018
528. WILMSHURTS, J.M., GUEKHT, A., SECCO, M., CROSS, H.J., & PERUCCA, E. (ADVOCACY TASK FORCE, COMMISSION ON PEDIATRICS, INTERNATIONAL LEAGUE AGAINST EPILEPSY). Advocacy for children with epilepsy: Leveraging the WHA resolution. *Advocacy Task Force, Commission of Pediatrics, International League Against Epilepsy. Epilepsia Open (Oxford)*

3,167-174, 2018

529. KRAUSS, G.L., PERUCCA, E., KWAN, P., BEN-MENACHEM, E., WANG, X., F., SHIH, J.J., PATTEN, A., JANG, H., WILLIAMS, B. & LAURENZA, A. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. *Epilepsia (Oxford)* 59, 866-876, 2018
530. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., SABERS, A., THOMAS, S.V., PERUCCA, E and VAJDA, F. for THE EURAP STUDY GROUP. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol. (London)* 17, 530-538, 2018
531. HELMSTAEDTER, C., BEGHI, E., ELGER, C.E., KALVIAINEN, R., MALMGREN, K., MAY, T.W., PERUCCA, E. TRINKA, E. and WITT, J.A. No evidence of a causal role of antiepileptic drug treatment with regard to the development of dementia. *J. Am. Geriatr. Soc. (New York)* 66,1850-1852, 2018
532. BIALER, M., JOHANNESSEN, S.I., KOEPP, M.J., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE, H.S. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. *Epilepsia (Oxford)* 59, 1811-1841, 2018
533. BIALER, M., JOHANNESSEN, S.I., KOEPP, M.J., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE, H.S. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. *Epilepsia (Oxford)* 59, 1842-1866, 2018
534. PERUCCA, E. Drug interactions with carbamazepine: An ever expanding list? *Epilepsy Res. (Amsterdam)* 147:119-120, 2018
535. PERUCCA, E. From clinical trials of antiepileptic drugs to treatment. *Epilepsia Open (Oxford)* 3 (Suppl 2), 220-230, 2018
536. PUTIGNANO, D., CLAVENNA, A., CAMPI, R., CANEVINI, M.P., VIGNOLI, A., BATTINO, D., BEGHI, E., PERUCCA, E., BORTOLOTTI, A., FORTINO, I., MERLINO, L. and BONATI, M. Perinatal outcome and healthcare resource utilization in the first year of life after antiepileptic exposure during pregnancy. *Epilepsy Behav. (Amsterdam)* 92:14-17, 2019
537. ZACCARA, G., MULA, M., FERRO', B., CONSOLI, D., ELIA, M., GIALLONARDO, A.T., IUDICE, A., LA NEVE, A., MELETTI, S., TINUPER, P., ZUMMO, L. and PERUCCA, E. Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy? *Epilepsia (Oxford)* 60, 175-183, 2019
538. MARTOS MARTINEZ-CAJA, A., DE HERDT, V., BOON, P., BRANDL, U., COCK, H., PARRA, J., PERUCCA, E., THADANI, V. and MOONS, C.P.H. Seizure-alerting behavior in dogs owned by people experiencing seizures. *Epilepsy Behav. (Amsterdam)* 94,104-111, 2019
539. BIALER, M., JOHANNESSEN, S.I., KOEPP, M.J., LEVY, R.H., PERUCCA, E., TOMSON, T. and WHITE, H.S. A summary of data presented at the XIV conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. *Epilepsy Res. (Amsterdam)* 153, 66-67, 2019
540. TOMSON, T., BATTINO, D. and PERUCCA, E. Teratogenicity of antiepileptic drugs. *Curr. Opin. Neurol. (Philadelphia)* 32, 246-252, 2019
541. MULA, M., ZACCARA, G., GALIMBERTI, C.A., FERRO', B., CANEVINI, M.P., MASCIA, A., MECARELLI, O., MICHELUCCI, R., PISANI, L.R., SPECCHIO, L.M., STRIANO, S., and PERUCCA, E. Validated outcome of treatment changes according to International League against Epilepsy criteria in adults with drug resistant focal epilepsy. *Epilepsia (Oxford)* 60, 114-1123, 2019
542. PERUCCA, P. and PERUCCA, E. Identifying mutations in epilepsy genes: Impact on treatment selection. *Epilepsy Res. (Amsterdam)* 152, 18-30, 2019
543. DAL RE, R., AVENDANO-SOLA, C., BLOECHL-DAUM, B., DE BOER, A., ERIKSSON, S., FUHR, U., HOLM, S., JAMES, S.K., MENTZ, R.J., PERUCCA, E., ROSENDAAL, F.R. and TREWEEK, S. Low risk pragmatic trials do not always require participants' informed consent. *Brit. Med. J. (London)* 364: I1092, 2019
544. FISHER, R.S., CROSS, H., DSOUZA, C., FRENCH, J.A., HAUT, S., HIGURASHI, N., HIRSCH,

E., JANSEN, F.E., PELTOLA, J., MOSHE, S.L., PERUCCA, E., LAGAE, L., ROULET-PEREZ, E., SCHULTZE-BONHAGE, A., SCHEFFER, I.E., SOMERVILLE, E., SPERLING, M.R., WIEBE, S., YACUBIAN, E.M. and ZUBERI, S. 2017 International League against Epilepsy classification of seizures and epilepsy are steps in the right direction. *Epilepsia (Oxford)* 60, 1040-1044, 2019

545. WIEBE, S., PERUCCA, E. and MOSHE, S. The ILAE at 110-Reflections on the last decade. *Epilepsia Open (Oxford)* 4:247-253, 2019

546. MESRAOUA, B., DELEU, D., KULLMANN, D.M., SHETTY, A.K., BOON, P., PERUCCA, E., MIKATI, M.A., and ASADI-POOYA, A.A.. Novel therapies for epilepsy in the pipeline. *Epilepsy Behav. (Amsterdam)* 97:282-290, 2019.

547. WILLIAMS, S., HOSSAIN, M., FERGUSON, L., BUSCH, R.M., MARCHI, N., GONZALEZ-MARTINEZ, J., PERUCCA, E., NAJIM, I.M. and GHOSH, C. Neurovascular drug biotransformation machinery in focal human epilepsies: Brain CYP3A4 correlates with seizure frequency and antiepileptic drug therapy. *Mol. Neurobiol. (Berlin)* 56, 8392-8407, 2019

548. PERUCCA, E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. *Epileptic Disorders (Montrouge)* 21, 319-329, 2019

549. TOMSON, T., BATTINO, D., BONIZZONI, E., CRAIG, J., LINDHOUT, D., PERUCCA, E., SABERS, A., THOMAS, S.V., PERUCCA, E and VAJDA, F. for THE EURAP STUDY GROUP. Declining malformation rates with changed antiepileptic drug prescribing: An observational study. *Neurology (Minneapolis)* 93, e831-e840, 2019

550. FRANCO, V. and PERUCCA, E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. *Drugs (Auckland)* 79, 1435-1454, 2019

551. FISHER, R.S., CROSS, H., DSOUZA, C., FRENCH, J.A., HAUT, S., HIGURASHI, N., HIRSCH, E., JANSEN, F.E., PELTOLA, J., MOSHE, S.L., PERUCCA, E., LAGAE, L., ROULET-PEREZ, E., SCHULTZE-BONHAGE, A., SCHEFFER, I.E., SOMERVILLE, E., SPERLING, M.R., WIEBE, S., YACUBIAN, E.M. and ZUBERI, S. Classification as autonomic versus sensory seizures. *Epilepsia (Oxford)* 60, 2003-2005, 2019

552. AUVIN, S., FRENCH, J., DLUGOS, D., KNUPP, K.G., PERUCCA, E., ARZIMANOGLOU, A., WHALEN, E., SHELLHAAS, R.A. Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: A consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). *Epilepsia Open (Oxford)* 4,537-543, 2019

553. ROMOLI, M., PERUCCA, E. and SEN, A. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. *Epilepsy Behav. (Amsterdam)* 2020;103(Pt A):106861.

554. FRENCH, J.A., PERUCCA, E. Time to start calling things by their own names? The case for antiseizure medicines. *Epilepsy Curr. (London)* 20,69-72, 2020

555. PERUCCA, E., BRODIE, M.J., KWAN, P. and TOMSON, T. 30 years of second-generation antiseizure medications: impact and future perspectives. *Lancet Neurol. (London)* 19, 544-556, 2020

556. PERUCCA, P., ANDERSON, A., JAZAYERI, D., HITCHOCK, A., GRAHAM, J., TODATO, M., TOMSON, T., BATTINO, D., PERUCCA, E., FERRI, M.M., ROCHTUS, A., LAGAE, L. CANEVINI, M.P., ZAMBRELLI, E., CAMPBELL, E., KOELEMAN, B.P.C., SCHEFFER, I.E., BERKOVIC, S.F., KWAN, P., SISODIYA, S.M., GOLDSTEIN, D.B., PETROVSKI, S., CRAIG, J., VAJDA,F.J.E., O'BRIEN, T.J., EpiPGX and EPIGEN Consortia. Antiepileptic drug teratogenicity and de novo genetic variation load. *Ann Neurol. (Boston)* 87, 897-906, 2020

557. FRANCO, V., BARUFFI, K., CREMA, F., MARCHISELLI, R., FATTORE, C., ROMIGI, A., DE GIORGIS, V., TARTARA, E., ELIA, M., D'AVOLIO, A. and PERUCCA, E. Determination of perampanel in dried plasma spots: Applicability to therapeutic drug monitoring. *Ther Drug Monit. (New York)* 42, 309-314, 2020

558. FRANCO, V., GATTI, G., MAZZUCHELLI, I., MARCHISELLI, R., FATTORE, C., ROTA, P., GALIMBERTI, C.A., CAPOVILLA, G., BECCARIA, F., DE GIORGIS, V., JOHANNESSEN-LANDMARK, C. and PERUCCA, E. Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. *Epilepsia* 2020, e79-e84, 2020.

559. FRENCH, J.A., BRODIE, M.J., CARABELLO, R., DEVINSKY, O., DING, D., JEHI, L., JETTE, N., KANNER, A., MODI, A.C., NEWTON, C.R., PATEL, A.A., PENNELL, P.B., PERUCCA, E., SANDER, J.W., SCHEFFER, I.E., SINGH G., WILLIAMS, E., WILMSHURST, J. and CROSS, J.H. Keeping people with epilepsy safe during the Covid-19 pandemic. *Neurology (Minneapolis)* 94, 1032-1037, 2020
560. BIALER, M. and PERUCCA, E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. *Epilepsia (Oxford)* 61, 1082-1089, 2020
561. PERUCCA, E. and BIALER, M. Critical aspects affecting cannabidiol oral bioavailability and metabolic elimination, and related clinical implications. *CNS Drugs (Auckland)* 34, 795-800
562. FRANCO, V., CANEVINI, M.P., DE SARRO, G., FATTORE, C., FEDELE, G., GALIMBERTI, C.A., GATTI, G., LA NEVE, A., ROSATI, E., SPECCHIO, L.M., STRIANO, S., TINUPER, P., PERUCCA E. for the SOPHIE STUDY GROUP. Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial. *Neurology (Minneapolis)* 95, e239-e246, 2020.
563. ASADI POOYA, A. A., BENICZKY, S., RUBBOLI, G., SPERLING, M.R., RAMPP, S. and PERUCCA, E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. *Epilepsia (Oxford)* 2020 Online ahead of print.
564. FRANCO, V., GERSHKOVICH, P., PERUCCA, E. and BIALER, M. The interplay between liver first-pass effect and lymphatic absorption of cannabidiol and its implications for cannabidiol oral formulations. *Clin. Pharmacokinet. (Auckland)* 2020, Online ahead of print

Projects MAIN RESEARCH ACTIVITIES/ACHIEVEMENTS

Dr. Peruccas research activities and main achievements have focused on the following areas (cited ref # refer to the list of articles in the Publications file)

- 1) Characterization of the pharmacokinetics of antiepileptic drugs (AEDs). Findings of these studies include the identification of (i) the mechanisms underlying the non-linear kinetics of phenytoin in humans (#18), the non-linearity of the pharmacokinetics of carbamazepine (#26), alterations in the pharmacokinetics of AEDs in children (#239,295,325,337,353,473), the elderly (#69,148,331,342,351,377,473), pregnant women (#21,31,41,65,370) and patients with associated disease (#76,118);
- 2) Identification of pharmacokinetic and pharmacodynamic interactions with AEDs. Some of the most significant contributions of these studies include the determination, for the first time, of the comparative enzyme inducing potencies of AEDs and their relationship with dose (#73), the characterization of the interactions between several AEDs and steroid oral contraceptives (#25,265,323,381), and the therapeutic synergism between valproic acid and lamotrigine in patients with refractory partial-onset seizures (#266);
- 3) Characterization of the relationship between serum drug levels and clinical effects of AEDs (#72,77,83,134,156,179) and other drugs, particularly antipsychotic agents (#282,292). Contributions related to this topic also include the only randomized controlled trial conducted to date on the clinical impact of therapeutic drug monitoring (TDM) in patients with newly diagnosed epilepsy (#278), studies on interlaboratory-variability in the determination of AEDs (#28,153,154,327) and co-authorship to the ILAEs position paper on the use of TDM (#408);
- 4) Development of innovative techniques to determine pharmacodynamic activity in early clinical development. Contributions in this area include the measurement of effects on interictal EEG spike discharges as a model for the early testing of potential AEDs in patients with epilepsy (#10), and the simultaneous assessment of isoproterenol-induced tremor and tachycardia in healthy subjects as a tool to quantify the relative cardioselectivity of beta-adrenergic blocking drugs (#33,35);
- 5) Design and conduction of randomized controlled trials in epilepsy and other conditions. Findings of trials completed in patients with epilepsy include (i) the superiority of vigabatrin over placebo in reducing the frequency of refractory partial-onset seizures (#108); (ii) the modest anti-absence effect of levetiracetam over placebo in children with newly diagnosed childhood and juvenile

absence epilepsy (#444); (iii) the ineffectiveness of intravenous phenytoin as prophylaxis against the occurrence of status epilepticus in patients undergoing supratentorial surgery (#310); (iv) the non-superiority of add-on treatment compared to alternative monotherapy in patients who failed AED monotherapy (#338); (v) the comparable efficacy of lamotrigine and sustained-release carbamazepine in elderly patients with newly diagnosed epilepsy (#393,429); (vi) the non-inferiority of levetiracetam compared with sustained-release carbamazepine in newly diagnosed epilepsy (#387); (vii) demonstration that vagal nerve stimulation improves quality of life over and above what can be achieved with standard medical care (#482). Other randomized controlled trials have allowed to demonstrate the efficacy of propranolol and metoprolol in the treatment of essential tremor ((#32,51,53), the superiority of primidone over phenobarbital in the treatment of essential tremor, using a design that documented for the first time a therapeutic action of primidone independent from metabolically derived phenobarbital ((#121), the ability of a ginseng extract to improve psychomotor performance in healthy subjects ((#98), and the effectiveness of lidocaine in reducing the intensity of tinnitus (#85).

Related work in the area on clinical trial methodology includes the production of documents aimed at improving clinical trial design and the efficiency of drug development in epilepsy (#412.435 465,500). One of these documents was highly influential in the process that led the U.S. Food and Drug Administration to permit the granting of a monotherapy license for AEDs in focal epilepsies based on extrapolation of results from adjunctive-therapy trials ((#500).

6) Characterization of the adverse effects of AEDs. The most important contribution in this respect stems from findings from the EURAP registry on the effect of intake of AEDs during pregnancy on the developing fetus. These findings include the documentation of major differences in teratogenic risk not only across drugs, but also in relation to AED dose taken at the time of conception (#451,529,534), the demonstration that teratogenic risk associated with prenatal exposure to AED polytherapy relates more to the presence of valproic acid in the treatment regimen than to polytherapy per se (#494), and the demonstration that type of treatment selected and treatment changes during pregnancy can have a profound influence on seizure control (#510). Another important finding from these studies is the demonstration that AED polytherapy and occurrence of major congenital malformations in previous pregnancies predict the risk of intrauterine death in AED-exposed pregnancies ((#495). Additional significant contributions to research on the adverse effects of AEDs include the first large-scale investigation on the antidiuretic effect of carbamazepine, and its relationship with serum drug levels (#14,30), the documentation of pseudo-atrophy of the brain as a rare adverse effect of valproic acid (#246), an assessment of the comparative effects of lamotrigine and carbamazepine on ECG parameters in the elderly (#420), a large prospective study on vigabatrin-induced visual field defects (#398,425), and a prospective investigation on factors affecting susceptibility to adverse effects in a population of over 1,000 consecutive patients with epilepsy enrolled at tertiary care centers (#434, 437, 457).

7) Initiatives aimed at improving quality of epilepsy care and epilepsy research. Dr. Perucca's role in the ILAE leadership during the last 10 years resulted in several initiatives aimed at raising the public visibility of epilepsy and implementing actions to improve epilepsy care and epilepsy research at a global level. These actions required intensive advocacy and coordination work on behalf of ILAE and led to two major achievements, the Written Declaration of Epilepsy ultimately approved by the European Parliament in 2011 (#458,477) and the Resolution on Epilepsy voted unanimously by the World Health Assembly (WHA) in 2015 ((#497,527). The European Declaration resulted in the European Commission allocating over 60 million for epilepsy research over the next 4 years, while the WHA Resolution led to several actions to improve medical and social services for epilepsy in several countries. Another relevant initiative was the establishment, jointly with IBE, of International Epilepsy, which since 2015 is celebrated annually worldwide in the first week of February (# 488). Other significant activities in this area were the development of many position papers, consensus documents and clinical guidelines intended to improve the quality of epilepsy care and research. Most significant examples are discussed in the section below (#380, 383, 384,408,419,427 461,462, 469,472,483,484,501,504,518, 519,536,540)

CONTRIBUTION TO THE PRODUCTION OF GUIDELINES AND POSITION PAPERS BY SCIENTIFIC SOCIETIES

In his capacity as member of the ILAE leadership since 2009 and as ILAE President during the 2013-2017 term, Dr. Perucca played an important role in spearheading the development of documents which have a important impact on epilepsy research and care worldwide. Examples include the development and validation of the definition of pharmacoresistant epilepsy (#427, 536, 540), the operational definition of epilepsy (#483, 484), and the new ILAE classification of the epilepsies (#518,519), and the classification of hippocampal sclerosis (#472. These documents have been highly influential as they impact how epilepsy is diagnosed and classified by health professionals. Other influential work in this area related to the review and production of clinical guidelines (#380, 383, 384,408,419, 461, 462, 469,501,504) intended to improve quality of epilepsy care in specific situations such as treatment selection in newly diagnosed epilepsy (#380,469), utilization of generic products of AEDs (# 384), the management of epilepsy during pregnancy, labour and puerperium (#419), the treatment of status epilepticus in adults (#383), AED selection in people with HIV infection (#461,462), use of therapeutic drug monitoring in patients receiving AEDs (#408), and access to physical exercise ad sports for people with epilepsy (# 459,505).

TEACHING AND TRAINING ACTIVITIES

Since 1981 Dr. Perucca has been a faculty member of the School of Medicine in the University of Pavia, Italy, where he taught Pharmacology and Clinical Pharmacology in several courses directed to medical students. For the past 10 years, his main teaching assignments were in the Pharmacology, Pharmacokinetics, Drug Discovery/Development ad Clinical Pharmacology modules in the Harvey Course in Medicine and Surgery at the University of Pavia. All teaching activities in the Harveys Course are done in English.

Dr. Perucca is also a member of the faculty of the Schools of Specialization in Neurology, in Child Neuropsychiatry, Pharmacology, Oncology, Genetics and Internal Medicine at the University of Pavia. In this position he contributes to teaching/training activities in areas related to pharmacology and drug therapy (about 30 postgraduate trainees per year).

Dr. Perucca is a member of the Teachers/Trainers College of the Doctorate on Life Sciences at the University of Pavia, and has been personally involved in the training of postgraduate students (about one PhD student trained in epilepsy-related research topics per year over the last 10 years). The Doctorate also has exchange/collaborative programs with other Universities, and has contributed to the training on epilepsy-related topics of PhD students from the University of Concepcion, Chile, the Hebrew University of Jerusalem, Israel, the University of Sao Paulo, Campus of Ribeirao Preto, Brasil, and the University of Madaba, Jordan.

Dr. Perucca also contributed regularly over the years to international epilepsy courses organized by EUREPA, ILAE, the European Epilepsy Academy (EUREPA), the Asian-Oceanian Epilepsy Academy (ASEPA), the Latin American Summer School on Epilepsy (LASSE) and ILAE Chapters worldwide. This has included, among other activities, the organization of the biannual courses "Pharmacological Treatment of Epilepsy", in Eilat and Jerusalem, Israel (2005, 2007, 2009, 2011, 2013, 2015, 2017, 2019), and the co-direction of the EUREPA (currently VIREPA) Distant Education Courses on Clinical Pharmacology and Therapeutics of Epilepsy.

Memberships

MEDICAL LICENCES

Italian Medical Council, Italy (since 1975)

General Medical Council, UK (since 1976)

MEMBERSHIP TO SCIENTIFIC SOCIETIES

British Pharmacological Society (1978)

British Pharmacological Society, Clinical Section (1978)

Italian Pharmacological Society (1981)

Italian Society of Clinical Pharmacology (1981)

Italian League against Epilepsy (1982)

Italian Society of Clinical Biochemistry (1992)
European Epilepsy Academy (1994)

POSITIONS WITHIN SCIENTIFIC SOCIETIES

2017 to-date Past-President, International League against Epilepsy

2009 2017 WHO Focal Person, International League against Epilepsy International League against Epilepsy

2013 -2017 President, International League against Epilepsy

2013 - 2013 Treasurer, International League against Epilepsy

2009 2013 Chair, Finance Committee, International League against Epilepsy

2010 - 2013 Co-Chair, Joint Task Force of the International League against Epilepsy and the International Epilepsy Bureau for Epilepsy Advocacy in Europe

2005 2009 First Vice-President, International League against Epilepsy

CURRENT EDITORIAL APPOINTMENTS

Member of the Editorial/Advisory Boards of *Epilepsia*, *Acta Neurologica Scandinavica*, *CNS Drugs*, *Epileptic Disorders*, *Epilepsy Research*, *Seizure*, *Lancet Neurology*, Expert Reviews in *Neurotherapeutics*, *Clinical Pharmacokinetics*, *Therapeutic Advances in Drug Safety*, *Clinical Drug Investigation*. *European Neurological Journal*, *International Journal of Epilepsy*, *Neurosciences*, *World Journal of Pharmacology and Clinical Investigation*.

APPOINTMENTS WITH REGULATORY AGENCIES

2001- to-date Member, List of External Experts, European Medicines Agency (EMA)

2001-2009 Member, Subcommittee for Licensing Authorizations, Italian Medicines Agency (AIFA), Italian Ministry of Health

2002-2004 Member, Subcommission for European Affairs, Italian Medicines Agency (AIFA), Italian Ministry of Health

[Other Relevant Information](#)